¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/30 ¤W¤È 09:15:57
²Ä 4583 ½g¦^À³
|
¤Ñ©R¤j¡A§A¯uªº«D±`¦³¦ò¤ß¡A¤@¦A¸ÑÄÀ³o¨Ç§A¦»¡©ú¹Lªº°ÝÃD ¨ä¹ê¡AY·Ó1bªº¼Æ¾Ú±Àºt¨ìphase 2 ³oÃĪ«¥i¥H»¡¤w¸g99¢H¦¨¥\¤F §â´XÓÃĪ«¼Æ¾Ú¦n¦n¬ãŪ¡A´N¯àÅé·|¤Ñ©R¤jªºW¤f±C¤ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gyang10150461 |
µoªí®É¶¡:2021/9/30 ¤W¤È 09:09:37
²Ä 4582 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j EASI90 P=0.245, ,没¹LÃö IGA 0,1 P=0.301, ,没¹LÃö ¬O¦]¬°³Qç9¤H°£«D¶Ç²Î-¤¤««×ADÃö«Y¶Ü? ÁÂÁ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 08:48:08
²Ä 4581 ½g¦^À³
|
µ²½×: ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ,³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
°ò½uEASI:
600mg vs ¹ï·Ó²Õ ITT 27.6 vs 29 RITT 30.5 vs 31.5 ç°£9¤H 19.9 vs 18.2
°ò½uIGA3/IGA4
ITT 68%/32% vs 67%/33% RITT 56%/44% vs 54%/46% ç°£9¤H 100%/0% vs 100%/0%
µ²½×: ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ,³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
³Qç°£9¤H.
°ò½u¥§¡EASI 19.9 vs 18.2
°ò½u100%¬Ò¬OIGA 3
P.15
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 08:27:26
²Ä 4580 ½g¦^À³
|
¬õ¹Ð¤j,
---------------¹LÃö¼Ð·Ç P<0.05--------
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
p.12 Study has 80% power to detect 39% improvement in EASI from baseline, compared to placebo, based on a one-sided 5% significance level
p.16 Mean change in EASI from baseline(EASI¥§¡°´T) ITT P<0.023 ¹LÃö.
---------------¹LÃö¼Ð·Ç P<0.05--------
Mean change in EASI from baseline (EASI¥§¡°´T)¬ODupilumab 2b,N=380(65*6²Õ),16¶g ¥Dn«ü¼Ð.
Primary Outcome Measures : Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16 [ Time Frame: Baseline to Week 16 ] The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
clinicaltrials.gov/ct2/show/NCT01859988?term=NCT01859988&draw=2&rank=1 ----------------------------------------------------
¥»¦¸ ITT(N=38)*8¶gªvÀø ---------------¹LÃö¼Ð·Ç P<0.05--------
EASI¥§¡°´T P=0.023 ,¹LÃö EASI50 P=0.016 ,¹LÃö EASI75 P=0.018, ,¹LÃö
Mean change in peak P-NRS P=0.032 ,¹LÃö Mean change in POEM from baseline P=0.014,¹LÃö -------------------------------------------------------------------- EASI90 P=0.245, ,没¹LÃö (2b N=60:60 ,16¶gªvÀø ,¦ô ASLAN004 62% VS ¹ï·Ó²Õ8% P<0.001,¹LÃö)
IGA 0,1 P=0.301, ,没¹LÃö (2b N=60:60, 16¶gªvÀø ,¦ô ASLAN004 64% VS ¹ï·Ó²Õ10% P=<0.001,¹LÃö)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/30 ¤W¤È 06:51:15
²Ä 4579 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j EASI/50.75..90ªº«ü¼Ð¶·¹F¨ì¦U爲¦h¤Ö¬O³q¹L¸Ñª¼¦¨¥\ªº¼Ð·Ç ©Î¦U¶µ«ü¼Ð»Ý¹F¦h¤Ö¤~ºâ¸Ñª¼¹LÃö §Ú·Q¤ñ¸û¤@¤U³o¦¸004¸Ñª¼¹LÃö¬O§C¼ÐÁÙ¬O°ª¼Ð
·PÁÂ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤U¤È 04:13:21
²Ä 4578 ½g¦^À³
|
Ävª§Àu¶Õ¦b¦¹ Dupilumab ²Ä¤@¶g600mg,¨ä¥L300mg/2¶g
¤£´±¥Î«¾¯¶q¡A²Ä¤G/²Ä¤T¶gx600mg,结½¤ª¢¨î¦í¡C
Lebrikizumab ²Ä¤@/²Ä¤G¶gx500mg ,¨ä¥L250mg/2¶g¡C (¤T´Á©ñ±ó¥|¶g¤@°w)
MOAµLªk§¹¥þ«ÊªýIL4°T®§¶Ç»¼¡C ¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 2b Á{§É³]p¥X²{
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
³Ì·s¤½¥q³ø§i
p.26
¤À¤²Õ¦@¦¬300¤H*16¶gªvÀø
1.300mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3000mg 2.400mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3600mg 3.400mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3000mg 4.600mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3600mg 5.¹ï·Ó²Õ
¤¤断²v׬°1/16=6.3%(±µªñDupilumab 3´Áq2w¤¤断²v7%)
¼ÒÀÀITT¡A¡«á«ü¼Ð¦p¤U
ASLAN004 600²Õ ,¨Ï¥ÎRITT+REEPP«á¡A¤¤Â_²v6.3% EASI 50 94%(RITT-REEPP) EASI 75 79%RITT-REEPP) EASI 90 40%(RITT-REEPP) IGA 0,1 48%(RITT-REEPP)
¥¼¨Ó16¶gªºªvÀø(ITT) ASLAN004 ¡«áIGA 0,1 /EASI90 ±N©Ô¤ÉÂ÷EASI75¤ñ²v79%®t12%/14%ªº68%/66% ¡K¡K¡K¡K¡K¡K IGA4 44%(°ò½u)¤W¤É¦Ü48%(¦PDupilumab ¤T´Á) ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K EASI75 ¦ô°¦Ü75% vs dupilumab 50% EAS¤u90 62% vs dupilumab36% IGA0,1 64% vs dupilumab 38%
¥H¤W¬OASLAN004 ¥¼¨Ó2b/P3 ªº³Ì·s预¦ô |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤U¤È 03:35:29
²Ä 4577 ½g¦^À³
|
红쯤j¡A
EASI75(¤T´Á¥Dn«ü¼Ð) ASLSN004 75% vs dupilumab 50%
¾Ö¦³1.5»õ¬ü¤¸²{ª÷¥i¥Î¡C «Ü§Ö·|«¦^¦~½u3.¬ü¤¸¡C
µ¥¬üªÑéw¡C
.³Ì·s±À¦ô
1¡BLebrikizumab AD2b Á{§É¡A60.6%/71%=85.3%(2b¡«áEASI75¤ñ/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½u¤uGA,0/1=3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F85.3%¡A °ò½uIGA4ªÌ¡A¡«á¹FEASI75=¦ô0%
2.dupilumab 3´ÁÁ{§É 50%/52%=96%(p3¡«áEASI75¤ñ/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½u¤uGA,0/1=3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F96%¡A °ò½uIGA4ªÌ¡A¡«á¹FEASI75=¦ô0% (ªvÀø«á没¤H¥i¹FEASI75)
------- 3.ASLAN004 2b/P3 300mg *Q2W*16¶g(ITT)
IGA4 =48%, IGA3=52%,(°ò½u)
¡«áEASI75=75%
¡«á(EASI75 75%/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¥i¨Ï°ò½uIGA3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F100%¡A
°ò½uIGA¡A0/1=4ªÌ¡A¡«á¹FEASI75=23%/48%=48%, ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½uIGA4««×AD±wªÌ¡A¡«áEASI75 ¥i¹F48%¡A
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/9/29 ¤U¤È 12:03:27²Ä 132 ½g¦^À³
¼ÒÀÀASLAN004 2b,P3, ITT¡A¡«á«ü¼Ð¦p¤U
ASLAN004 EASI75= 75% vs dupilumab(¤T´Á) 50% ASLAN004 EASI90= 62% vs dupilumab 36% ASLAN004 IGA0,1= 64% vs dupilumab 38%
¥H¤W¬OASLAN004 ¥¼¨Ó2b/P3 ªº³Ì·s预¦ô
1.¨ÌRITT¬°°ò¦,¤¤断²v¥»¬°3/16=19%,׬°1/16=6.3%,±µªñDupilumab 3´Áq2w¤¤断²v7%. 2.´£°ª°ò½uIGA 4 ¦Ü48%,쬰44%. ¦PDUPILUMAB ¤T´Á¤ñ²v
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/29 ¤U¤È 03:30:08
²Ä 4576 ½g¦^À³
|
·PÁ¤ѩR¤j¸Ô²Óªº¾ÉŪ¦UÃĪ«¼Æ¾Ú¡A§â¸ê®Æ¼Æ¾Ú¥J²Ó¤ñ¸û¤F¤@µf ·|¾ÉP°ª¤ñ²vµ²½¤ª¢ªºDupilumab¡A¤£¬O¤£¥i«_¥Ç¤F
¦U¦w¤Ñ©R¡B¦U¦ÛÀH½t |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/29 ¤U¤È 03:22:10
²Ä 4575 ½g¦^À³
|
ªÑ»ù«Ü®e©ö¤Þ°_§ë¸ê¤Hªº¤£²z©Ê ¨ì²{¦b§Ú³£ÁÙı±o¤j¶^©M¸Ñª¼µ²ªG ¨S¦³µ´¹ïªºÃö«Y ³oºØ½L¬O¦³«¤jªº§QªÅ¡A©Î¤½¥q§ÖˤF¤~ ·|¥X²{ªº¡A¦Ñ·à¦³³o麽¤jªº§QªÅ¶Ü¡H ¤j¶^²Ä¤@¤p®Éªº¤j¶q¬O½Ö¦b¦Y³f ·|¬O´²¤á¶Ü¡H ¦pªG¬O¿ù±þ¡AÀ³¸Ó«Ü§Ö·|¦³¤ÏÀ³ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤U¤È 03:17:58
²Ä 4574 ½g¦^À³
|
REGN ¤½¥q(dupilumabªº¤½¥q)600¦h¬ü¤¸/ªÑ¡A³Ì¨Î§ë¸êÂI2011¦~«e¡C(50¬ü¤¸¥ª¥k)
·sÃħë¸ê
Á{§É¦¨¥\²v+¤j¥«³õ¦û¦³²v¡K¡K¤W¥««á¤j卖
ªk°ê赛¿Õµá2005¦~¤JªÑREGN(20¬ü¤¸/ªÑ)¡A¦û20%¡A Áȳ̦h¡A«ùªÑ16¦~¡A¤µ¦~«Å¥¬n½æ¥X¤@¥b¡A REGNµo¦æ¯S§OªÑ¶R¤U¥¦¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ASLN ¥b¦~«á¨B¤J³Q«Å¥¬¨ÖÁÊ´Á¡AÀH®É¥i¯àµo¥Í¡C(¤@¤Ñ¨ì¦ì)
«D¬ü区±ÂÅv¡K¡K¦ô©ú¦~©³ 2b¸Ñª¼¡K¡K¦ô«á¦~ªì
Äw资4-5»õ¬ü¤¸°µAD¤T´Á¡C
¥H¤WªÑ»ù¤è¯à¦³¤jº¦ªº题¤~¡C(Ó¤H¬Ýªk)
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/29 ¤U¤È 02:52:13
²Ä 4573 ½g¦^À³
|
·PÁ¤ѩR¤j¤@ª½À°¤j®a¤ÀªR¼Æ¾Ú ¯uªº§Æ±æ¨È·à±d¯à¦³¤@Ó¦nªºµ²ªG ¤j®a¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤U¤È 02:42:02
²Ä 4572 ½g¦^À³
|
¨È狮¸gÀç¹Î¶¤¬O«Ü¦³¸gÅ窺¹Î¶¤¡C
3¤ë¥÷§Q¥ÎEEPP¶Ò资+É´Ú¤w¨ú±o1.5»õ¬ü¤¸资ª÷¡C ITT¼W¥[3/16=18%ªº¤¤Â_²v纳¤Jp¹ººâ¡A©Ò¦³«ü¼ÐÀø®Ä¤j°¡C
(¦ýDupilumab 3´Á¡AQ2w组220¤H¤¤断²v¶È7%)
¹B®ð¤£¦n¡A¦³¤@¤¤¤ß©Û¶Ò9¤H«D¶Ç²ÎAD±wªÌ¡A¦Ó¦b¸Ñª¼«e¾Dç°£¡C
ITT38¤HªºÀø®Ä¤w±µªñduoilumab,
8¶gvs16¶gªvÀø(§t¤¤断²v12%®t²§¡A¥¼³Qç°£9¤H)
³o¼Ë¥´¥EASI75 50%¯uªº«Ü¼F®`¡C ¡K¡K¡K¡K ITT 38¤H(©Ò¦³¶i¤JªvÀø¤H) EEPP 32¤H¡Aç°£6¦ì¤¤断ªvÀø¥BªvÀø¥¼¹F29¤ÑªÌ¡C RITT 29 ¤H¡A¦b¸Ñª¼«e¡A¥Î°ò½u¥Íª«¼Ð»xç°£¤@Ó9¤HªºÁ{§É¤¤¤ß¡A¦]©Ò©Û¶Ò¬ÒÄÝ«D¶Ç²Î¤¤««×AD¯f¤H¡C(¦ý¥]§t6¦ì¤¤Â_ªvÀø¨«ªÌ)
¤Ö¤H¼ÆªºÁ{§É«È©ö¨ü²§±`ȼvÅT¡C ¥ÎITT¯àp<0.05¤w¸g«Ü¼F®`¤F¡C
1b AD¥D¨¤ ¦w¥þ©Ê EASI ¥§¡°´T EAS¤u75 ¬Ò¹LÃö¡C
2b¦A±´Q2w/Q4w³Ì¨ÎÀøªk.¤w锁©wÃĪ«¦¨¥»½d³ò¡C
n¨ÖÁʪº¤jÃļt¤w¨¬°÷资®Æ¤F¡C
ITT,RITT,EEPP ,MOA....
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/9/29 ¤U¤È 02:34:19
²Ä 4571 ½g¦^À³
|
TO:ª©¥D¤j¤H
½ÐÀ°¦£±N¼ÐÃD§ï¬°ASLN004¤@´Á¸Ñª¼¥¿¦V,¦ý¤´¦³«Ý¥«³õ»{¦P,§Æ±æ§ë¸ê¤H³£¯à¥þ¨¦Ó°h
¼ÐÃD¤º®e¦p¤U: 2021.09-¤@´Á¼Æ¾Ú²³ø:ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/29 ¤U¤È 02:24:24
²Ä 4570 ½g¦^À³
|
§Ú»{¦P©t¨à¤j §Ú¤]ºâ¬O³Ì¦§ë¸ê·à¤lªº¤@§å,«ùªÑ¤]¦Û»{¤£¤Ö ³o¦¸¼Æ¾Ú¤½¥¬¤§«á,«H¤ß¶}©l¥Ë¸Ñ ¸Ñª¼¥¢±Ñ¤]¶^,¦¨¥\¤]¶^ ¥u¯à»¡·sÃĬãµoÁÙ¬O¤£®e©ö ©Î³\¤j®a¤£¸Ó¦A¦p¦¹¼ÖÆ[¬Ý«Ý§a(¦X²z»ù?¨ÖÁÊ?)
§ë¸ê·à¤l °£¤F¦~ªì¨ºªi,¤@ª½¥H¨Ó·à¤l³£¬OÅý¤j®a¥¢±æªº ¤§«e¦b¤U¥«Âà´«ÁÙÅý¤j®a§éÄË¥b¤Ñ ÁÙ¦n§Ú¦b¥xªÑªºÀò§Q«j±j¯àcover·à¤l·l¥¢ ¤£¹L³Ìªñ¯uªº¬O¦³ÂI²Ö¤F... ©Î³\µ¥¤£¨ì·à¤l¦¨¥\¤§®É,¦bªÑ»ù¦³ÂI°_¦â®É´N·|·Q½æ¥X¤F§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/9/29 ¤U¤È 01:17:32
²Ä 4569 ½g¦^À³
|
²{¦bı±o§ë¸ê¦Ñ·à¡A¤w¸g¬O½äª`±o¦¨¥÷°ª¤F~~²¦³º¥¼¨Ó2©Î3´Á«á¡An¤ñ§ù¥²ª¢¦³®Ä©Ê°ª«Ü¦h¡AÃø«×¤]«Ü°ª~~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 11:33:59
²Ä 4568 ½g¦^À³
|
Proportion of patients with 50%, 75%, and 90% improvement in the EASI score (EASI50, EASI75, and EASI90) weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ]
¥H¤W¥u¦³8¶gªº°O¿ý. --------------------------------- n¬Ý16¶gµ²ªG, nµ¥2bÁ{§É,12~15Ó¤ë«á. --------------------------------
clinicaltrials.gov/ct2/show/NCT04090229
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
Primary Outcome Measures : To assess the safety and tolerability of multiple ascending doses of ASLAN004: Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Baseline to 12 weeks safety follow up ] Incidence of treatment-emergent adverse events (TEAEs) reported from the administration of study drug on Day 1 until the completion of the study.
Secondary Outcome Measures : Percentage change from baseline in Eczema Area and Severity Index (EASI) score weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ]
Proportion of patients with 50%, 75%, and 90% improvement in the EASI score (EASI50, EASI75, and EASI90) weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ]
Percentage change from baseline in the Pruritus Numerical Rating Scale (NRS) score weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ]
Proportion of patients with at least a 4-point improvement in the Pruritus NRS score weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ]
Proportion of patients who achieve an Investig ator Global Assessment (IGA) score of 0 or 1 weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ] Percentage change from baseline in the Patient-Oriented Eczema Measure (POEM) weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ]
Percentage change from baseline in percent body surface area (%BSA) affected weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ]
PK parameters throughout the dosing period, and serum concentrations by scheduled timepoints. [ Time Frame: Baseline to 12 weeks safety follow up ]
Measurement of area under the curve (AUC) at Week 8 (AUC0-last), maximum observed concentration (Cmax) at Week 1, time to Cmax (tmax) at Week 1, Ctrough throughout the dosing period, and serum concentrations by scheduled timepoints.
Change from baseline in PD markers of allergic inflammation (TARC and total IgE) weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ] Measurement of absolute values of TARC and total IgE in serum concentration and percentage of change
Measurement of ASLAN004 Anti-Drug Antibody over time. [ Time Frame: Baseline to 12 weeks safety follow up ] Measurement of ADA levels in serum |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/29 ¤W¤È 11:20:02
²Ä 4567 ½g¦^À³
|
¬Ý¬Ý¦~©³¬O§_·|¦³16¶gªº¼Æ¾Ú¡A¥|¤j«ü¼Ð¬O§_¥i¥H¦A¥[15¢H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 11:12:15
²Ä 4566 ½g¦^À³
|
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
¦³x®É¶¡§Ç¦C,ªº¦U«ü¼ÐyÁÍ¶Õ ¹Ï,
0/4/8/12/16 ¶g. ¥idownload ÀÉ®×¥h¬Ý
Lebrikizumab 2b , Q2W*250MG ,
IGA 0,1 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.6%
EASI50 ²Ä8¶g¦b¬ù70%,²Ä16¶g81.0%
EASI75 ²Ä8¶g¦b¬ù44%,²Ä16¶g60.6%
EASI90 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.0%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G±áÄf10141758 |
µoªí®É¶¡:2021/9/29 ¤W¤È 10:52:46
²Ä 4565 ½g¦^À³
|
«e°}¤l¤£¬O¦³´£¨ìµo¦æªºÅvÃÒ¡A³ÌªñªºªÑ»ù¬O¤£¬O³QÅvÃÒ¨é°Ó©MªÅ¤èµ¹¶Â±¼©O¡H¦]爲¼Q¤W¥h¥LÌn½ß§ó¦h¡K.ÁÙ¦³¥D¤Oª¾¹D¼Æ¾Ú«Ü´Î©Ò¥H¶¶¶Õ¬G·N¨Ó˳f¬~¹S½X¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 10:11:46
²Ä 4564 ½g¦^À³
|
¥»¦¸¤½§GITT EASI¥§¡°´T/EASI50/ EASI75=50%(vs Dupilumab3´Á 50% ¤@¼Ë¨Î¡A¤¤断²vY¤@¼Ë¡AASLAN004¦A¤W¤É12%.¹F62%)
¦bN=38¤H¡A22vs16¡C
P<0.05
·§©À©ÊÁ{§É¦¨¥\¡C(MoA½T¥ß)
EASI90,IGA0,1, 2b©ñ¤j¤H¼Æ60:60 P<0.001 16¶gªºªvÀø·|¤j´T©Ô°ª¡C
³o¼ËªºITT¡«á«ü¼Ð´N¦n¨ì´Î´Î¥s¡I
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K RITT¤ÎEEPP ¬O预¦ô2b¦A¦¸¦¨¥\ªº¨Ì¾Ú¡A ¥¼¨Óªº¥i¯à¼Æ¾Ú¡A¦³¦h»ò°ª¡C
¤j®a¦A«ä¦Ò¤@¤U¡A¤£n³QªÑ»ùÀ~¨ì¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/29 ¤W¤È 10:07:01
²Ä 4563 ½g¦^À³
|
³oÓ»ù®æ¡A½ä®{®t¤£¦h¥i¥H¶i³õ¤F ¥H¤p·i¤j¡A½ß²v«Ü°ª ¬O¤@ӫܦnªº½ä³Õ¼Ðªº¡A¤ñ½ä±mª÷¡AĹªº ¾÷·|¤j¦h¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 09:41:02
²Ä 4562 ½g¦^À³
|
¤w¤T¤jÃĦ¨¥\¤T´ÁÁ{§ÉªºM0A¬OASLAN004¦¨¥\ªº«Oµý¡C ·í§A¬Ý¤£À´MOA´N®e©ö³QªÑ»ù¼vÅT¡C
¦Ê¦~Ãø±o¤@¨£ªº§ë¸ê¼Ð¦a¡C
Dupilumab 结½¤ª¢°Æ§@¥Î¡AÃø¦pASLAN²Ä¤@¡B¤G¡B¤T¶g¥Î600mg,¨ÓªvÀøIGA4ªº««×AD¡C
¦p¼ÒÀÀIGA4(°ò½u)¡A¡«áEASI75 50% vs dupilumab 0% ¡K¡K¡K¡K¡K¡B
¬ÝÀ´¼v¤ù¤~¬Oªø§ë°ò¥»¥\,
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¤@¡BII«¬¨üÅé(TYPE II RECEPTER): ¡X¡X¹L±Ó©Êµoª¢¤ÏÀ³ ¸ô®|:
¤»Ó¥D¨¤: °tÅé : (1)IL-4(¤¶¥Õ¯À4¸¹) ,(2)IL-13 (¤¶¥Õ¯À13¸¹) ¨ü¾¹ : (3)IL-4R£\ , (4)IL-13 R£\1 (5)II«¬¨üÅé (TYPE II RECEPTER): (²Õ¦¨ A : IL4 ±µ¦XIL-4R£\ ¦A±µ¦X IL-13 R£\1) (²Õ¦¨ B : IL13 ±µ¦XIL-13R£\1 ¦A±µ¦X IL-4 R£\)
(6)pSTAT6
1. IL-4¤ÎIL-13 ¬Ò¥i ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³ , ¦³¥H¤UA¡BB¨â±ø¸ô®|
A: ¥ÑIL-4 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé) (3). II «¬¨üÅé±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
B: ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé) (3). II «¬¨üÅé ±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤G丶Dupilumab¤ÎASLAN004 ¬Ò¥i¦P®ÉªýÂ_IL4¤ÎIL13 °T®§¶Ç¾É¸ô®|
Dupilumab µ²¦XIL-4R£\ & ASLAN004 µ²¦XIL-13 R£\1¤§¾÷Âà(MOA) ¬Ò¥i¦P®ÉªýÂ_ II«¬¨üÅ餧²Õ¦¨¦ÓÁקKÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6)¤§¬¡¤Æ¡A¤]ÁקK¹L±Ó©Êµoª¢¤ÏÀ³. ¨Ï±oA&B ¸ô®|¤¤¤£²£¥Í(2)~(5)¸ô®|¡C
¤T¡BLebrikizumab & Tralokinumab M〇A , ¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/29 ¤W¤È 09:33:52
²Ä 4561 ½g¦^À³
|
1b´N¥u¬O¦btry¡A¬Ý¼ç¤O¡B§ä¥X³Ì¦nªºªvÀø¤è¦¡¡BÆ[¹î°Æ§@¥Î ¥H¨Ï2´Áªº¹êÅç§ó¶¶§Q...
¦U¦ÛÀH½t°Õ¡A¦Ü¤Ö³o¤£¥Î¹³ÀùÃÄ¡A¤@µ¥3-5¦~ªº |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 09:18:12
²Ä 4560 ½g¦^À³
|
©ú¤Ñ¤j¡A
¦pªG³o¬O¥þ·sªº·sÃÄ¡A§Aªº¨ÌªÑ»ù³¯z¦ü¥G¦³¹D²z¡C
¦ý³oÓType IIªºMOA ¤w¾ú¸gdupilumab/Lebrikizumsb/Talo¤T¤jÃĪº¤T´ÁÁ{§É¬Ò¦¨¥\¡C
Áo©ú¦³¸gÅ窺·sÃħë¸ê¤H¡Aª¾¹D¨ä¦¨¥\²v¡C
Á{§É¼Æ¾Ú¬O¬ì¾Çªº®Ú¾Ú¡C
¤@¤ÁÀH缘¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30
²Ä 4559 ½g¦^À³
|
¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/29 ¤W¤È 08:51:54
²Ä 4558 ½g¦^À³
|
¤Ñ©R¤j ªñ´XÓ¤ë·s¥[©Y¿D¬w¬ü°ê¬Ì±¡¤SÃzµo¡A³oÓ¦]¯À·|¤£·|¬O³y¦¨¦³¨Ç¨ü¸ÕµLªk¦^¶E°lÂÜÀËÅçÆ[¹î¦Ó¬y¥¢¡A¼vÅT¼Æ¾Ú¯u¹ê©Ê? «Ü¥i³ßªº昰2bÁ{§É¸ÕÅç300¤H §Y±N¦b²Ä¥|©u®i¶}¡A§Æ±æ¤½¥qª`·N¬Ì±¡ÅܤơA¦¬®×Âå°|§ä¬Ì±¡Áͽwªº¦a°Ï¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 08:15:17
²Ä 4557 ½g¦^À³
|
¤¤断²v׬°1/16=6.3%(±µªñDupilumab 3´Áq2w¤¤断²v7%)
¼ÒÀÀITT¡A¡«á«ü¼Ð¦p¤U
ASLAN004 600²Õ ,¨Ï¥ÎRITT+REEPP«á¡A¤¤Â_²v6.3% EASI 50 94%(RITT-REEPP) EASI 75 79%RITT-REEPP) EASI 90 40%(RITT-REEPP) IGA 0,1 48%(RITT-REEPP)
¥¼¨Ó16¶gªºªvÀø(ITT) ASLAN004 ¡«áIGA 0,1 /EASI90 ±N©Ô¤ÉÂ÷EASI75¤ñ²v79%®t12%/14%ªº68%/66% ¡K¡K¡K¡K¡K¡K IGA4 44%(°ò½u)¤W¤É¦Ü48%(¦PDupilumab ¤T´Á)
EASI75 ¦ô°¦Ü75% vs dupilumab 50% EAS¤u90 62% vs dupilumab36% IGA0,1 64% vs dupilumab 38%
¥H¤W¬OASLAN004 ¥¼¨Ó2b/P3 ªº³Ì·s预¦ô
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/9/29 ¤W¤È 08:14:23
²Ä 4556 ½g¦^À³
|
To: ¤p©ú¤j
1.1B¼Æ¾Ú¸Ñª¼¥¿¦V¡AªÑ»ù¯à¶^¦¨³o¼Ë¡A¥Nªí¤½¥q®Ú¥»¶Ã·d¡A¦b§Ú¬Ý¨Ó½Ð¦³¤O¤H¤h¥[¤J¤½¥q¬°004I®Ñ(¥Î¼Æ¾Ú»¡¸Ü¤ñ¸û¦³¥Î¡A¨Ò¦¹¦¸EASI-90¤ÎIGA¥O¥«³õ¥¢±æ¡AY¦³¤O¤H¤h¦³¥Îªº¸Ü¡A¬°¤°»òªÑ»ùÁÙ¶^?)¡A¬O®ö¶O¤½¥q¸ê·½©~¦h¡C 2.¥¼¨Ó2´Á©Ò¥Îªº¾¯¶q¡A«e¤T¶g¥Î°ª¾¯¶qæí¿@«×¬O¹ïªº¡A¦ý¾ãÓÀøµ{¾¯¶q¬Ý¨Ó¨ÃµL¤Ö©ó§ù¥²ª¢¡A¦ýÀ³¸Ó¨S®t¡A²¦³º¶¡¹j¬I¥´®É¶¡¤Î¦³®Ä©Ê(§t°Æ§@¥Î)¤~¬O¯f±wÄ@·N¿ï¾ÜÀøµ{ªºÃöÁä¡C 3.¦Ü©ó¥ý«eªø®Mªº§Ú¡A¬Ý¨Ó§Ú¥u¯à¦Aµ¥2´Á´Á¤¤¡AY¥«³õ¤´¤£»{¦P¡A´N·í¥´¤ôº}°Õ!!!
¥H¤W¨Ñ°Ñ¦Ò~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/29 ¤W¤È 08:11:08
²Ä 4555 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 07:44:45
²Ä 4554 ½g¦^À³
|
clinicaltrials.gov/ct2/show/results/NCT02277743?view=results
Dupilumab ¤T´Á ¤§¤@solo1 ¤¤Â_²v
Qw组 26/223=12% Q2w²Õ16/224=7% ¹ï·Ó组 40/222=18%
ASLAN 004
¹êÅç组3/16=19% ¹ï·Ó组3/13=23% ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥¼¨Ó¤T´ÁASLAN004ªº¤¤Â_²v·|¤j°¦Ü7%¥H¤U¡A ©Ò¦³ITTªºÀø®Ä·|¥[¼¤W¤É12%.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/9/29 ¤W¤È 07:29:13
²Ä 4553 ½g¦^À³
|
½Ð°Ý©t¨àÃĤj
¹ï004ÃĪº¬Ýªk¡AÁ¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤W¤È 03:49:48
²Ä 4552 ½g¦^À³
|
ASLAN004 600²Õ ,¨Ï¥ÎRITT+EEPP«á EASI 50 100%(RITT-EEPP)(¤À¥À¦©°£3¦W--(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô)) EASI 75 85%(RITT-EEPP) EASI 90 46%(RITT-EEPP) IGA 0,1 54%(RITT-EEPP)
¥Ó½ÐÃįgªº°ò¦¬OITT¡C
EEPP ¡G¥Î©ó´ú¸Õ¥DnÀø®Ä²×ÂI
¥H«á2b/PHASE3¡A RITTªº¤j¼Æ¾Ú·|ªñ¦üITT¡C ©Ò¦û¤ñ¨Ò¤p´N¤£¥Îç°£¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/29 ¤W¤È 12:08:06
²Ä 4551 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j¡A 4546½g¡ARITT¤À¥À¦A´î3¤H(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô)´N«Ü¦³½ì¡A¤½¥q¬°¤°»ò¤£³o¼Ë°µ¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/28 ¤U¤È 11:21:20
²Ä 4550 ½g¦^À³
|
«Ó°¶¤j ¤µ¤é¤@¶}½L3¤ÀÄÁ§Ú´N¥ý½æ±¼3¸UªÑ¤F,§¡»ù2.1x¦©±¼¤âÄò¶O,ÁȤF2¤d¦h¬üª÷~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/9/28 ¤U¤È 11:02:22
²Ä 4549 ½g¦^À³
|
¦pªG¼Æ¾Úµ²ªG¤£¤ñ¹ï¤â®t ¬°¦óªÑ»ù¦p¦¹¤ÏÀ³ ¨ÃµLÁ٨䤽¹D ÁÙ¬O¥~°ê§ë¸êªÌ¬Ý¨ì¤£¦Pªº±¦V ©Î¬O§ó²`¨Iªº°ÝÃD¦s¦b |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/28 ¤U¤È 10:53:37
²Ä 4548 ½g¦^À³
|
·Q½Ð±Ð©ú¤Ñ¤j ±z¬Q¤é·mµuªº¤µ¤Ñ·|¦p¦ó¾Þ§@ Äò©ñµ¥¤Ï¼uÁÙ¬O·|§Ôµh±þ¥X? YÄò©ñ±zÁÙ·|¦Ò¼{¥[½X¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/28 ¤U¤È 10:44:50
²Ä 4547 ½g¦^À³
|
¤@´ÁÁ{§É©Û¶Ò¨ü¸Õ¯f±w°ò¦¤ñ¸û
(A) Mean ESAI score Dupliumab ¤@´Á ¹êÅç²Õ 30.2-- 26.8 ¹ï·Ó²Õ 32.7--28.9 ASLAN 004 ¤@´Á¹êÅç²Õ 30.5 ¹ï·Ó²Õ 31.5
ASLAN 004 ©Û¶Òªº¨ü¸Õ¤ñDupliumab ÄY«¤@¨Ç
(B) NRS ¤ñ¸û The NRS is comprised of one item and represents the numbers 0 (¡§no itch¡¨) to 10 (¡§worst imaginable itch¡¨). Subjects are asked to rate the intensity of their itch using this scale. It features high reliability and concurrent validity and is a popular choice for all patients due to its simple format.
NRS <3 - mild pruritus »´«× NRS > 3 < 7 - moderate Pruritus (Dupliumab ¤@´Á ¹êÅç²Õ 6.3 - 5.9 ¹ï·Ó²Õ 6.1-5.5 ¨ü¸ÕÄݩ󤤫ׯf±w) NRS > 7< 9 - severe Pruritus (ASLAN 004 ¤@´Á¹êÅç²Õ 7.5 ¹ï·Ó²Õ7.9 ¨ü¸ÕÄÝ©ó««×¯f±w) NRS > 9 - very severy pruritus ·¥««×
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤U¤È 10:35:40
²Ä 4546 ½g¦^À³
|
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
P.13
Evaluable for Efficacy as Per Protocol (EEPP)
3¤ë1¤é´Á¤¤³ø§i¬O¥ÎEEPP
EEPP required patients to complete at least 29 days treatment / assessment (used for testing the primary efficacy endpoint) • 4 patients withdrew2 due to flare or lack of improvement of disease symptoms ( 2 patients from placebo arm and 2 patients from 600mg arm)
• 2 patients withdrew due to major protocol deviations
EEPP n¨D±wªÌ§¹¦¨¦Ü¤Ö 29 ¤ÑªºªvÀø/µû¦ô ¡]¥Î©ó´ú¸Õ¥DnÀø®Ä²×ÂI¡^ • 4 ¦W±wªÌ¦]¬ðµo©Î¯e¯f¯gª¬¥¼§ïµ½¦Ó°h¥X2----(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô) ¡]¦w¼¢¾¯²Õ 2 ¦W±wªÌ©M 600mg ²Õªº 2 ¦W±wªÌ¡^
• 2 ¦W±wªÌ¦]ÄY«ªº¨óij°¾®t¦Ó°h¥X ----(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô) ¡]¦w¼¢¾¯²Õ 1 ¦W±wªÌ©M 600mg ²Õªº 1 ¦W±wªÌ¡^
ASLAN004 600²Õ ,¨Ï¥ÎEEPP«á EASI 50 89%(EEPP)(¤À¥À¦©°£3¦W--(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô)) EASI 75 58%(EEPP) EASI 90 32%(EEPP) IGA 0,1 37%(EEPP) ¥§¡EASI°´T -73%(EEPP)(P.16)
µ²½×: ¦]¬°9¤ëITT ºâªk¤À¥À¥]§t(3¦W¥¼§¹¦¨29¤ÑªvÀø/µû¦ô))©M 3¤ëªºEEPP( ¥¼§t¥¼§¹¦¨29¤ÑªvÀø/µû¦ô), ¤£¦P ¬G¬Ý°_¨Ó¦³¨ÇÀø®Ä«ü¼Ð(EASI50//EASI¥§¡°´T)¦³ÅÜ®t.
¥t¥~RITT¬O¦X²zªºç°£«D¶Ç²Î-««×AD(6+3)¦W±wªÌ. YRITT ¤À¥À¦A´î3¤H,´N«Üº}«G
RITT--EEPP
ASLAN004 600²Õ ,¨Ï¥ÎRITT+EEPP«á EASI 50 100%(RITT-EEPP)(¤À¥À¦©°£3¦W--(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô)) EASI 75 85%(RITT-EEPP) EASI 90 46%(RITT-EEPP) IGA 0,1 54%(RITT-EEPP) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤U¤È 08:26:14
²Ä 4545 ½g¦^À³
|
www.marketbeat.com/stocks/NASDAQ/ASLN/price-target/?RegistrationCode=SocialMedia-direct&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia
ASLAN Pharmaceuticals¡¦s buy rating reiterated at HC Wainwright. $8.00
ú³°ÓHC Wainwright¤µ¤éµo§G , ºû«ùASLN ¥Ø¼Ð»ù8¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/28 ¤U¤È 08:23:34
²Ä 4544 ½g¦^À³
|
Dupilumab ¤@´ÁÁ{§É¼Æ¾Ú »P ASLAN004 ¤@´ÁÁ{§É¼Æ¾Ú¤ñ¸û«ÈÆ[
www.nejm.org/doi/full/10.1056/nejmoa1314768 (ªí¤G)
finance.yahoo.com/news/aslan-pharmaceuticals-announces-positive-data-100000377.html ASLAN004 ¤@´Á¦b8¶g®Éªº IGA 0/1 (%) , EASI-75 (%) »P Dupilumab ¤@´Á12¶gÁ{§É¼Æ¾Ú¤À®x§Ü§
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/9/28 ¤U¤È 04:24:20
²Ä 4543 ½g¦^À³
|
ASLAN ³Q¨ÖÁÊ»ù®æ±À¦ô±ø¥ó¡G 1.ÁÉ¿Õµá§ùÁת¢12¦~±M½æ´Á¶¡¡A¾P°âÃB¦ô¬ù850»õ¬ü¤¸ (2017~2021¾P°âÃB133»õ¬ü¤¸)¡C 2.·sÃĤò§Q«O¦u¥H65%pºâ(·sÃĤò§Q³£¤K¦¨¥H¤W)¡C 3.ASLN 004 ¥þ²y¥«¦û²v¦ô3/5
ASLN 004¾P°â12¦~(±M½æ´Á)²b§Q¦ôp¡G850*(3/5)*65%=331»õ¬ü¤¸ 1.ASLAN²b§Q¦Ü¤Ö331»õ¬ü¤¸(¥¼ºâý³Ý¡B003)¡A§A·|ªá¦h¤Ö¿ú¨ÖASLAN? 2.«O¦u¥H50»õ+ý³Ý©M003¦@10»õ=60»õ¬ü¤¸³Q¨Ö¡C(¦X²z¶Ü?) ´«ºâ¦¨ADRªÑ»ù¬ù86¤¸(60»õ/69.62M=86)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/28 ¤U¤È 04:23:04
²Ä 4542 ½g¦^À³
|
²³øp.27ªº¼Æ¾Ú¡AY¬Ý¦¨¤@¤å¤£È¡A¨º¤]ÀH½t¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤U¤È 03:47:10
²Ä 4541 ½g¦^À³
|
¸Ø±i¤j¡A
ASLAN004,6-12Ó¤ë¬O¦X²zªºµû¦ô¨ÖÁʮɶ¡¡C
§Æ±æ©ú¦~©³«D¬ü区¾P°â±ÂÅv«e¥i§¹¦¨³Q¨ÖÁÊ¡C
·§©À©ÊÁ{§É¤w§¹¦¨¡AMOA½T»{¡C
¤S§ä¨ì°ª¾¯¶q600mg¡A§C°Æ§@¥Î¡AªvÀøIGA4 ADÀøªk¡C
¤jÃļt¤w¥iµû¦ô¨ÖÁʤè®×¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/28 ¤U¤È 03:42:29
²Ä 4540 ½g¦^À³
|
§Ú²q¨È·à±dÀ³¸Ó·|§â«ÂIÂà¨ìASLAN003¤F,¤½¥q³Ì«áªº©R¯ß.... ¤½¥q·|³Q¦X¨Ö¬O¦³¥Lªº»ùÈ,¦ý¨È·à±d¥¼¨Ó³Q¦X¨Öªº¾÷²vÁͪñ©ó¹s ! ¥B¤â¤WªºÃÄ¥u³Ñ¤U¨âºØ 004¤w¸g³Q¥«³õÄY«½èºÃ,003©Î³\ÁÙ¦³¤@½u¥Í¾÷! ¤µ±ßªÑ»ù¬O¤@ÓÃöÁä,¦pªG¯}©³Â½ªí¥Ü¦³§ë¸êªÌ³{§C¶R¤J©|¦³¤@½u¥Í¾÷~ ¦ý¦pªG¤@¼Ë«ùÄò¯}©³,´N¤£±Æ°£¤U±´USD1.2 §Ú¤]¦b²î¤W·nÂ\..«ùÄòÆ[¹î¤¤ !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/28 ¤U¤È 03:32:49
²Ä 4539 ½g¦^À³
|
1 ´Á©M 2 ´ÁÁ{§É¬ã¨sªº 119 ¦W¨ü¸ÕªÌ¤¤¡AASLAN003 ¤w³QÃÒ©ú¹ï°ª¹F 400 ²@§J/¤Ñªº¾¯¶q¨ã¦³¨}¦nªº@¨ü©Ê¡A¨Ã¥B¾A¥Î©ó¨C¤é¤@¦¸ªº¤fªAµ¹ÃÄ¡C§Ú̥ثe¥¿¦bºV©w ASLAN003¦b¦Û¨§K¬Ì©Ê¯e¯f¤¤ªºÁ{§É¶}µop¹º¡C
°ò
¥H¤W¬O¤½¥q©xºô¹ï003ªº´yz¡A¤°»ò®ÉÔ°µ¨ì 1¡B2´Á119¦W¨ü¸ÕªÌ¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/9/28 ¤U¤È 03:20:54
²Ä 4538 ½g¦^À³
|
±Ú¸sÂX¼W110.09.27¥¿¦V¼Æ¾Ú¤w¤½¥¬¡AASLA004¦w¥þ©Ê¡BÃĮġB¾¯¶q¬Ò¤w½T»{¡B ¨¬¥H°µ¬°¤¤jÃļtªº¡§¨ÖÁÊ¡¨¨Ì¾Ú¡C¡K¡K¡K(·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/3/15 ¤U¤È 12:44:43) ³Ì¦³¥i¯à³Q¨ÖÁʮɶ¡ÂI¹w´ú¡G 1.2bÁ{§É´Á¤¤³ø§i(111¦~6¤ë)¼Æ¾Ú¥X¨Ó«e³Q¨Ö¡G ·Q¨ÖASLNªº¤½¥q¡A·Qnª¾¹Dªº¼Æ¾Ú³£¦³¤F¡AYn¦Aµ¥ASLA004 2bÁ{§É´Á¤¤³ø§i¼Æ¾Ú¥X¨Ó¡A¥u·|ÅýASLN ¦h¼W¥[³Q¨ÖÁʽͧPªºÄw½X¡C 2. ASLA004 ©ú(111)¦~©³±ÂÅv«D¬ü¦a°Ï«e³Q¨Ö¡G ·Q¨ÖASLNªº¤½¥q¡A·Qnªº¼Æ¾Ú(2bÁ{§É´Á¤¤³ø§i¼Æ¾Ú)¤]³£¦³¤F¡AYn¦Aµ¥ASLN¥D°Ê´£¥X«D¬ü¦a°Ï±ÂÅv¤~¨Ö¡A·íµM¨ÖÁÊ»ù½X¤S±o´£°ª¡C
¥t¥~¡AÁÉ¿Õµá¨C©u¤½¥¬§ùÁת¢¾P°âÃB¡A³£¬OÅýASLNºCºC¹Ô°ª³Q¨ÖÁʽͧPªºÄw½X¡C
2Ó¥D°Ê¦¡¥XÀ»(2bÁ{§É´Á¤¤³ø§i¡B©ú(111)¦~©³±ÂÅv«D¬ü¦a°Ï)¡G¢¨Ï¼t°Ó»°§Ö¨ÖASLN(¤£»°§Ö¨Ö¡A§Ú(ASLN) ¥i¬On¤½¥¬Á{§É´Á¤¤¼Æ¾ÚÅo¡A§Ú(ASLN)·|½Õ°ª³Q¨ÖÁÊ°â»ù³á)¡C 6Ó³Q°Ê¦¡¨¾¿m(¨C©u¤½¥¬§ùÁת¢¾P°âÃB)¡GASLNºCºC¹Ô°ª½Í§PÄw½X¡C(¤£»°§Ö¨Ö¡A§Ú(ASLN)·|Ä~Äò°Ñ¦Ò§ùÁת¢¾P°âÃB¡A½Õ°ª³Q¨ÖÁÊ°â»ù³á) ~~~~~~~~~~~~~~~~~~~~~~~~~ASLN ¯¸¦b«Ü¦³§Q(³Q¨Ö)ªº¦ì¸m~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ §Ú»{¬°2bÁ{§É´Á¤¤³ø§i(111¦~6¤ë)¼Æ¾Ú¥X¨Ó«e³Q¨Öªº¾÷²v«Ü¤j¡A³Q¨ÖÁʮɶ¡ÂIÀ³¸¨¦b©ú(111)¦~²Ä¤@©u¡C ¶R®a¥ç¥i¯à´£¥XDD¡C (ÃĪ«¥»½è¤w¸g½T©w¡A¦b°Ó¨¥°Ó¡A¤£¥i¯àÅýASLN¤@ª½©ì®É¶¡¡AÄ~Äò®³¥X·sªº¼Æ¾Ú¥X¨Ó)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/28 ¤U¤È 01:20:42
²Ä 4537 ½g¦^À³
|
©Î³\¬O¦Ñ·à«e¬ì¬ö¿ý¤Ó¦h ¸Ñª¼«áªº¹w´Á¤ßùØ ¥«³õ±N¤p°ÝÃDµ¹©ñ¤j¸ÑŪ¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/28 ¤U¤È 12:00:41
²Ä 4536 ½g¦^À³
|
¨ä¹ê¬Q±ß¨S¥Xªº¤µ¤Ñ¤]¤£¥Î¥X¤F ¥u¬O¤£ª¾¤Snµ¥¦h¤[¡A³oÀYéw·à |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/9/28 ¤W¤È 11:46:54
²Ä 4535 ½g¦^À³
|
·PÁ¦U¦ì¤j¤j ¥Î¤ß·j¶°¤Î¤À¨É Åý§Úı±o¤@®§©|¦s ¤´¦³¥i¬°©Î©ñ¤â¤@·i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤W¤È 11:20:26
²Ä 4534 ½g¦^À³
|
¦b´¦ª¼«e»P¼Æ¾ÚºÊ´ú©eû·|°Q½×«á¡A×qªº ITT ¤H¸s¡]RITT¡An = 29¡^³Q©w¸q¬°±Æ°£¤@Ó¬ã¨s¦aÂI¡A¦b¸Ó¬ã¨s¦aÂI¡A®Ú¾Ú¥Íª«¼Ð»xª«¡A©Ò¦³°Ñ¥[¬ã¨sªº±wªÌ³£ªí²{¥X«D¨å«¬ªº¤¤«×¦Ü««× AD ±wªÌ¡A
¨Ò¦p TARC ©M±wªÌ¯f¥v2¡C¦b RITT ¤H¸s¤¤¡A»P¨ä¥L¤wµoªíªº¤¤«×¦Ü««× AD¬ã¨s3§ó¨ã¥i¤ñ©Ê¡AASLAN004»P¦w¼¢¾¯¬Û¤ñ¡A¦b EASI »P°ò½u¬Û¤ñªº¦Ê¤À¤ñÅܤƤ豤]¨ú±o¤F²Îp¾Ç¤WªºÅãµÛ§ïµ½¡]p<0.025 1¡^¡A¨Ã¥BÅã¥Ü¥X¤ñ¦w¼¢¾¯§ó¤jªº§ïµ½¦w¼¢¾¯¦bÃöÁäÀø®Ä²×ÂI»P ITT ¤H¸s¬Û¤ñ¡C Following discussions with the Data Monitoring Committee prior to unblinding, a Revised ITT population (RITT, n=29) was defined to exclude one study site at which all patients enrolled in the study appeared atypical of moderate-to-severe AD patients based on biomarkers, such as TARC, and patient medical history2. In the RITT population, which is more comparable to other published studies3 in moderate-to-severe AD, ASLAN004 also achieved a statistically significant improvement (p<0.0251) versus placebo in percent change from baseline in EASI and showed a greater improvement over placebo in the key efficacy endpoints versus the ITT population.
9/27·s»D½Z
p.14 Patients from other sites consistent with previous AD studies. All patients from Site X atypical of moderate-to-severe AD patients
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
¥Íª««ü¼Ð Serum ,ÄÝ»´¼xAD ±wªÌ,¶Ç²Î¤¤-««×AD±wªÌ,¦¹Ãþ«DASLAN004 ¥Ø¼Ð±wªÌ,ç°£¦X²z.
¤é«á¨ú±oÃĵý,n¥ÎASLAN004ªvÀø¤]µL³X.
¨Ì¾Ú¥Íª«¼Ð»x¡A §â¤£¬O«D¶Ç²Î¤¤-«¯gADç°£(¸û»´¯g)¡C
¤é«á2/3´Á¡A©Û¶Ò®É¥i¯à·|ç°£Serum ¥Íª«¼Ð»x§C«×ªÌ¡C¤ñ¸û²Å¦X¶Ç²Î¤¤««×AD±wªÌ¡CDupilumab ¤]测°ò½uSerum, ©Ò¥H¦³¼Æ¾Ú¥i¤ñ¸û¡C
³o¬O¤@¸s¦³¸gÅ窺ADÁ{§É领°ì±M®a©Ò¨M©w¡C
¨S¤°»ò¤j°ÝÃD¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/28 ¤W¤È 11:05:55
²Ä 4533 ½g¦^À³
|
³oÃä¤j¤j³£¤@ª½®i²{¨È·àªºÀuÂI... §Ú¨Ó¤@ÂI¤Ï±ªº«äºû ¨È·à±d¾ú¸g¤FGÀù¡BÁx¹DÀù¡B¨ÅÀù,©x¤è¤@¶}©l³£»¡¼Æ¾Ú«D±`ªº¦n~¦ýµ²½×...¤@¸Ñª¼´N¬O¥¢±Ñ ³o¤@¦¸¨È·à±d©~µM¥ý®g½b¦Aµe¹v,§â9¤H¥ý±Æ°£ªº¥Î·N¬O±Ë?¦pªG¼Æ¾Ú³£«D±`Àu¨}¬°¦ón§â9¤H¥ý±Æ°£? ¾ÉP³Ì«á¥«³õÁÙ¬O¤£±µ¨ü³o¼Æ¾Ú! ¥»¤H¬Q¤é2¶ô¶R¤J¥u¬O·Q¤pÁȵu½u...·m¶^²`¤Ï¼u,§Æ±æ¤µ¤ÑÄ~Äò¤Ï¼u«á´N·|½æ¥X! ¥Ã»·µ²§ô¨È·à±dªº®Èµ{ !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤W¤È 10:22:21
²Ä 4532 ½g¦^À³
|
Dupilumab ²Ä¤@¶g600mg,¨ä¥L300mg/2¶g
Lebrikizumab ²Ä¤@/²Ä¤G¶gx500mg ,¨ä¥L250mg/2¶g¡C (¤T´Á©ñ±ó¥|¶g¤@°w)
¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 2b Á{§É³]p¥X²{
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
³Ì·s¤½¥q³ø§i
p.26
¤À¤²Õ¦@¦¬300¤H*16¶gªvÀø
1.300mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3000mg 2.400mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3600mg 3.400mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3000mg 4.600mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3600mg 5.¹ï·Ó²Õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/9/28 ¤W¤È 10:17:22
²Ä 4531 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ASLAN004 ©ó©ú¦~6¤ë¦³µo¥¬ 2bÁ{§É´Á¤¤³ø§iªº¥²n©Ê¶Ü?
ÁÙ¬O»¡¤½¥q¥i¥H¿ï¾Ü¤£¤½¥¬. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤W¤È 10:02:57
²Ä 4530 ½g¦^À³
|
¤T´ÁªºÁ{§É¥Dn«ü¼Ð
EASI-75 IGA0¡A1 ¡A
2Ó400¤HÁ{§É¡A
¹êÅç组/¹ï·Ó组>1.5¿¡AP<0.001
¥Ø«eASLAN004¡A ¦ô¤T´Á EASI75=65%¡A¹ï·Ó组=15% ¡A65%/15%=4.3¿ IGA 0,1=52%¡P¹ï·Ó组10%,52%/10%=5.2 ¿¡C
Dupilumab ¬O¨ú±oBTD¡AASLAN004±NÀu©óDupilumab
¼Æ¾Ú¦n¤£¦n¡H §A¯uªº¦³¥Î¤ß¬ã¨sMOA,¾¯¶q¡A°Æ§@¥Î¡K¡K¤è¯à§PÂ_¡C
Dupilumab µ²½¤ª¢¯u¹ê¥@¬É¹Fªñ40%.
©Ò¥HµLªk¦pASLAN004,²Ä¤@¡B²Ä¤G¡B²Ä¤T¡B¶g³sÄò¥Î600mgªº°ª¾¯¶q¡A¨ÓªvÀøIGA4ªº«¯g¯f¤H¡C
³o´N¬OASLAN004ªºM0A¤Q°ª¾¯¶qªvÀø¤è®×¡C ¿W¯SÀu¶Õ¡I¿W¯SÀu¶Õ¡I¿W¯SÀu¶Õ¡I
ASLN ¶Ò资©ú¦~©³¶}©l¡A¥]¾P¨î¡A¦³¿úªº¨é°Ó¤~·|©Ô¨ì预°â»ù¤§¤W¡C
¥»¦¸¤w¤£¶Ò资ª÷¡AµL¤H©Ô»ù¡A¼Æ¾Ú¤@¤½§Gµu½u«È½æ¥X¡C
(¥H¤WÓ¤HÆ[¹î)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/9/28 ¤W¤È 09:57:33
²Ä 4529 ½g¦^À³
|
¤§«eÁx¹DÀù¥¢±Ñ«e¡A±Ò°Ê¤F004¡A¤§«e«Ü¤[¨S°Êªº003¬ðµM°Ê¤F¡A§Æ±æ¤£n¬O§Ú²q±o³o¼Ë!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/28 ¤W¤È 09:38:41
²Ä 4528 ½g¦^À³
|
¼Æ¾Ú¦n¦ý¦³¤ß¤Hn±þ½L¡A³o»¡¤£¹L¥h¡K°ò¥»¤W¬üªÑ´N¬O¤@¦¸©Ê¤ÏÀ³¡A¦n´N¬O©¹¤W¡AÃa´N¬O©¹¤U¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/28 ¤W¤È 09:25:07
²Ä 4527 ½g¦^À³
|
¬Q±ß¼É¶^¥X¤j¶q ¼Æ¾Ú¯uªº³o麽®t¶Ü¡H ÁÙ¬O¦³¤ß¤H¨è·N±þ½L ±µ¤U¨Óµ¥003¤½¥q¹ï¥~ªº»¡©ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤W¤È 09:06:58
²Ä 4526 ½g¦^À³
|
¦b´¦ª¼«e»P¼Æ¾ÚºÊ´ú©eû·|°Q½×«á¡A×qªº ITT ¤H¸s¡]RITT¡An = 29¡^³Q©w¸q¬°±Æ°£¤@Ó¬ã¨s¦aÂI¡A¦b¸Ó¬ã¨s¦aÂI¡A®Ú¾Ú¥Íª«¼Ð»xª«¡A©Ò¦³°Ñ¥[¬ã¨sªº±wªÌ³£ªí²{¥X«D¨å«¬ªº¤¤«×¦Ü««× AD ±wªÌ¡A
¨Ò¦p TARC ©M±wªÌ¯f¥v2¡C¦b RITT ¤H¸s¤¤¡A»P¨ä¥L¤wµoªíªº¤¤«×¦Ü««× AD¬ã¨s3§ó¨ã¥i¤ñ©Ê¡AASLAN004»P¦w¼¢¾¯¬Û¤ñ¡A¦b EASI »P°ò½u¬Û¤ñªº¦Ê¤À¤ñÅܤƤ豤]¨ú±o¤F²Îp¾Ç¤WªºÅãµÛ§ïµ½¡]p<0.025 1¡^¡A¨Ã¥BÅã¥Ü¥X¤ñ¦w¼¢¾¯§ó¤jªº§ïµ½¦w¼¢¾¯¦bÃöÁäÀø®Ä²×ÂI»P ITT ¤H¸s¬Û¤ñ¡C Following discussions with the Data Monitoring Committee prior to unblinding, a Revised ITT population (RITT, n=29) was defined to exclude one study site at which all patients enrolled in the study appeared atypical of moderate-to-severe AD patients based on biomarkers, such as TARC, and patient medical history2. In the RITT population, which is more comparable to other published studies3 in moderate-to-severe AD, ASLAN004 also achieved a statistically significant improvement (p<0.0251) versus placebo in percent change from baseline in EASI and showed a greater improvement over placebo in the key efficacy endpoints versus the ITT population.
9/27·s»D½Z
p.14 Patients from other sites consistent with previous AD studies. All patients from Site X atypical of moderate-to-severe AD patients
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
¥Íª««ü¼Ð Serum ,ÄÝ»´¼xAD ±wªÌ,¶Ç²Î¤¤-««×AD±wªÌ,¦¹Ãþ«DASLAN004 ¥Ø¼Ð±wªÌ,ç°£¦X²z.
¤é«á¨ú±oÃĵý,n¥ÎASLAN004ªvÀø¤]µL³X.
------------------------------------------ ¼Æ¾Ú¦nÃa¬O¤½¥q°ª¼h¤Î¨ÖÁʪ̦b¬Ýªº.¤@¯ë没²`¤J¬ã¨s§ë¸êªÌ,¤£©ö¬Ý¥X.
¤½¥q·s»D½Z:
---------------------------------------------------- ¸Ó¬ã¨sªº¼Æ¾Ú§¹¥þ¤ä«ù§Ú̪ºÆ[ÂI¡A§Y ASLAN004 ªº·s¾÷¨î¥i¥H¥Nªí¤¤«×¦Ü««× AD ±wªÌªº·sªvÀø¿ï¾Ü¡A
¦³¥i¯à´£¨Ñ¦P³Ì¨ÎªºÀø®Ä(best-in-class efficacy)©M¦P¯Å³Ì¨Îªº¦w¥þ©Ê¡C( best-in-class safety.) ----------------------------------------------------
ASLAN»sÃĤ½¥qº®uÂåÀø©xKen Kobayashi³Õ¤h»¡¡C
¡§§Úַ̫ܼN³ø§iASLAN004ªº¦p¦¹¥¿¦Vªº¼Æ¾Ú¡C
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ ¸Ó¬ã¨sªº¼Æ¾Ú§¹¥þ¤ä«ù§Ú̪ºÆ[ÂI¡A§Y ASLAN004 ªº·s¾÷¨î¥i¥H¥Nªí¤¤«×¦Ü««× AD ±wªÌªº·sªvÀø¿ï¾Ü¡A
¦³¥i¯à´£¨Ñ¦P³Ì¨ÎªºÀø®Ä(best-in-class efficacy)©M¦P¯Å³Ì¨Îªº¦w¥þ©Ê¡C( best-in-class safety.) @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ §ÚÌ´Á«Ý¦b¥¼¨Ó´X©P±Ò°Ê 2b ´Á¬ã¨s¨Ã±´¯Á¥i¥H¬°±wªÌ´£¨ÑÃB¥~«K§Qªº¨C¤ëµ¹ÃĤè®×®É¡A§Q¥Î³o¤@±j¤jªº¼Æ¾Ú¶°¡C¡¨
Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: ¡§We¡¦re delighted to report such positive data on ASLAN004. The data from the study wholly support our view that ASLAN004¡¦s novel mechanism could represent a new treatment option for patients suffering with moderate-to-severe AD, with the potential to deliver best-in-class efficacy and best-in-class safety. We look forward to building upon this strong data set as we initiate the Phase 2b study in the coming weeks and explore monthly dosing regimens that could provide additional convenience to patients.¡¨
finance.yahoo.com/news/aslan-pharmaceuticals-announces-positive-data-100000377.html
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤W¤È 08:43:48
²Ä 4525 ½g¦^À³
|
Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
°ò½uIGA 4=29%/IGA3=71%
60.6%(EASI75¤ñ²v)/71%(IGA3¤ñ²v)=85%
Dupilumab ¤T´Á ¥H¤Wªº¤ñ²v=96%
ASLAN004 1b ¥H¤W¤ñ²v100%
--------------------- EAS¤u75/IGA 4 °ò½u¤ñ Lebrikizumab 0%(°ò½uIGA4±wªÌ¡A¡«áEASI75 0%) Dupilumab 0%(¦P¤W0%) ASLAN004 30% (°ò½uIGA4¡A¡«á30%¹FEASI75)
Lebrikizumab ¶ÈAD³Q¨ÖÁÊ11»õ¬ü¤¸¡A¥Ø«e¦æ±¡¤wº¦¦Ü22»õ¬ü¤¸¡C
ASLAN004 Àø®Ä¤ñdupilumab°ª¤@级¡C ý³Ý¡ACOPD.....¦PDupilumab¦h¾AÀ³¯g ¬ü°ê¥¼¨ü±±±wªÌ420¸U¤H¡C
¥Ø«eDupilimab ¥þ²y300,000¤H¥Î¹L¡A¤w²Ö¾P100»õ¬ü¤¸¡A¬ü°ê¾P°â额¦û80%,¥¼¨Ó¦û120»õ¬ü¤¸³Ì°ª¾P°â¡C
ÀH«Kºâ50»õ¬ü¤¸ASLN³Q¨ÖÁÊ¡A¯uªº«K©y¡I
ªø§ëªÌ»{©wÁ{§É¼Æ¾Ú¤Î¥«³õ¡A¨ä¥L¥u¦³µ¥«Ý¡C
µu½u¯uªº«Ü¤£®e©ö´x´¤¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/28 ¤W¤È 08:29:26
²Ä 4524 ½g¦^À³
|
²{¦b¤@´Áè°µ§¹¡A¼Æ¾Ú¨S¦³¤ñ¸ûÀu¡A¤d¸U¤£n»¡³oÃĤñ¤°»ò¤w¸g¤W¥«¥¿¦b½æªºÃĦn¡A¦pªG¦n¬Q¤Ñ´N¬O¤j¼Q¡A¬Q¤é2¶ô¤jÁx¶R¶i¥u¬Oµu´Á¾Þ§@¡A¹wp¤T¶ô´N½æ¥X |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2021/9/28 ¤W¤È 08:20:28
²Ä 4523 ½g¦^À³
|
To ¤Ñ©R¤j,
¤@.ASLAN004 (8¶gªvÀø)EASI-75 69% (BASE LINE IGA 3/4 =56%/44%),
¥Nªí °ò½uIGA 3±wªÌ, 100%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
¥Nªí °ò½uIGA 4±wªÌ, 13%/44%=30%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
½Ð°Ý§A¤W±ªº±À¦ô¡A¬O¥H¥ÎÃÄ16©P¬°°ò·Ç±À¦ôªº¶Ü? ÁÙ¬O¥Î³o¦¸ªº¼Æ¾Ú¨Ó±À¦ô?
¥t¦A½Ð±Ð¤@¤U¡A³o¦¸004ªº¼Æ¾Ú¡ARITT ¦³±Æ°£9Ó¯f±w¡A¥ÎÃIJÕ6¤H¸ò¹ï·Ó²Õ3¤H¡A¬Û¹ïITT¦Ó¨¥RITT±o¨ì¼Æ¾Ú¤ñ¸û¦n¡A¦ý¬O¤]·|³Q±M®a½èºÃ¡A¬°¦ón±Æ°£¨º¤EÓ¤H¡A½Ð°Ý¤Ñ©R¤j¡A¤½¥q¬°¦ón¯S©w±Æ°£9¤H¡A¥hq¤@ÓRITT±Ú¸s©O? ³o¼Ë¬O§_·|³Q¨ä¥L±M®a½èºÃ¬ü¤Æ¼Æ¾Ú©O?
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/28 ¤W¤È 08:05:55
²Ä 4522 ½g¦^À³
|
m.investing.com/equities/immunomedics-historical-data
Immu ¤½¥q¡AIMMU132/ADC¡A³Q200»õ¬ü¤¸¨ÖÁÊ¡A¬ù87¬ü¤¸/ªÑ¡C
¤@ADCªv¥|´Á3½u«áBNTC¡A·sÃĤ½¥q¡A¥H2´ÁÁ{§É¥Ó½ÐÃĵý¡AÀòFDAªºBTD(¬ð¯}©ÊÀøªk)¡A
·í2015¦~ÀòBTD®ÉªÑ»ù¶È1.5¬ü¤¸/ªÑ¡A ´¿¸g±NIMMU132¥þ²y¾P°âÅv20¦h»õ¬ü¤¸±ÂÅv¥X¥h¡AªÑ»ùº¦¨ì25¬ü¤¸¡A«á¨Ó¤jªÑªF¶}°£CEO¡A¤£¦P·N±ÂÅv¦X约¡A¤½¥q³Ì«á2050¦~ÀòÃĵý¡AªÑ»ùº¦¨ì40¬ü¤¸¡A³Ì«á³Q¨ÖÁÊ»ù87¬ü¤¸¥ª¥k¡C
·sÃĤp¤½¥q´N¬O³Q¨ÖÁʪѻù³Ì°ª¡C
ASLN ¤½¥q¤w¶Ò+É资ª÷1.5»õ¬ü¤¸¡A¥i¥Î¨ì2023¦~©³¡C
¦A¨Ó2022¦~©³¡A«D¬ü区ªºASLAN004 ±ÂÅv¡A2b¸Ñª¼¡A须¶Ò资4-5»õ¬ü¤¸¡A¤è¯à±Ò°ÊAD¤T´Á¡C
±q²{¦b¶}©l¬Ò¬O¤jÃļt¨ÖÁÊASLNªº¦n¾÷·|¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K ¸¤H¤j¡A
û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/9/27 ¤U¤È 11:13:02²Ä 4510 ½g¦^À³
±À½×: ¦b°ò½u©Ô¥«á
ASLAN004 ¦b¤T´Á¥Dn«ü¼ÐEASI75 ¤´¦³30%~34% ªºIGA 4 ÄY«±wªÌ¹F¼Ð, Àu©óDUPILUMAB (¤T´Á±À¦ô)¥i¯àµL¥ô¦ó¤H¹F¼Ðªº¼ç¤O,
¨âÃĦb°ò½uIGA 3 ,¤¤«×±wªÌªvÀø«á¹F¼Ð¤ñ²v«h¬Û·í.
¥H¤Wµ²±À½×¦P3¤ë1¤éªº³ø§i±À½×没ÅÜ.
------------------- ¤@.ASLAN004 (8¶gªvÀø)EASI-75 69% (BASE LINE IGA 3/4 =56%/44%),
¥Nªí °ò½uIGA 3±wªÌ, 100%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
¥Nªí °ò½uIGA 4±wªÌ, 13%/44%=30%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
**********
¤G.Dupilumab ¤T´Á (16¶gªvÀø)EASI-75 50% (BASE LINE IGA 3/4 =52%/48%),
¥Nªí °ò½uIGA 3±wªÌ, 5%0/52%=96%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
¥Nªí °ò½uIGA 4±wªÌ, 0%/48%=0% ,µL¤H¥i¹F¦¨¤T´Á«ü¼ÐEASI75
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K IGA 0,1¡«á¡A¦b16¶g¡A·|¸ò¤WEASI75¤ñ²v¡C
Dupilumab ¤T´ÁEASI75=50%¡AIGA0,1=38%¡C
¦ôASLAN004 2/3´Á¡A°²³]°ò½u¦PDupilumab, EASI75=65%¡A IGA0.1=53%
¤ñDupilumab Àu¤@级¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2021/9/28 ¤W¤È 07:38:59
²Ä 4521 ½g¦^À³
|
To ¤Ñ©R¤j,
·Q½Ð±Ð¤@¤U¡A¬Q¤ÑASLN¤j¶^ªºì¦]¬O¬°¸ò§ùÁת¢¬Û¤ñ¡A¥H²³øP27¼Æ¾Ú¨Ó¬Ý¡AEASI-75©M IGA 0/1¡A¼Æ¾Ú¨Ã¨S¦³©úÅã¤ñ§ùÁת¢¦n¤W¤£¤Ö¡A§ùÁת¢ªº¼Æ¾Ú¬O¥ÎÃÄ16©P¡A¦ý¬O004¥u¦³8©P¡A¨âªÌ¬Û¤ñ¥H«ÈÆ[¨Ó¬Ý¡A¦n¹³¤£ºÉ¤½¥¡A¨º¬O§_¤½¥q¥¼¨Ó¡A·|Ä~Äò°lÂÜ1´Á³o¨Ç¯f±w¡A¥ÎÃÄ16©Pªº¼Æ¾Ú©O? §_«hnµ¥¨ì²Ä¤G´Á¡A¤~·|¦³16©Pªº¼Æ¾Ú¥i¥H¤ñ¹ï¡A²¦³º§ùÁת¢¬O²{¦b¤w¸g¦b¥«±¤W³c°âªº¼Ð¹vÃÄ¡A¦pªG004¼Æ¾Ú¨S¦³«Ü¬ð¥X¡A³o¼Ë«ÜÃøÅý¨Ï¥ÎªÌ¶R³æ¡Aı±o004·|¤ñ§ùÁת¢¨Óªº¦³®Ä©O?
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/28 ¤W¤È 06:28:42
²Ä 4520 ½g¦^À³
|
ÁöµM§Ú¬O§Û©³¶i³õ¡A¦ý¬O¦pªGµ²§½¬O¥¢±Ñ¡A ¨º«ùªÑ¦¨¥»¬O¦h¤Ö¥i¯à¤]¤£«n¤F ¥Í¦º¦³©R¡A´I¶Q¦b¤Ñ ¨M©wÄ~Äò¬Ý¤U¥h |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤W¯Z±Ú10146168 |
µoªí®É¶¡:2021/9/28 ¤W¤È 12:41:29
²Ä 4519 ½g¦^À³
|
¸òµÛÂà´«¨ì¬üªÑ©ê¨ì²{¦b,µ²ªGªÑ»ù³o¼Ë¤ÏÀ³,¯uÅý¤H±¡¦ó¥H³ô. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/28 ¤W¤È 12:19:44
²Ä 4518 ½g¦^À³
|
ªü´µÄõ¥¼¯à¥Î¯SÀ³©Ê¥Öª¢¼Æ¾Ú©Hý Dupixent ¹ï¯SÀ³©Ê¥Öª¢³]©wÁA¦p¦¹°ªªº¼Ð·Ç¡A¥ô¦ó«e¨Ó´M¨D«a°Ãªº¤H³Ì¦n°µ¦n·Ç³Æ¡C³o¥i¯à´N¬O³ò¶ Aslan Pharmaceuticals ªº¸ÕÅç³]p©Mµ²ªGªº°ÝÃD¾ÉP¸Ó¶°¹ÎªÑ»ù¤U¶^ 31% ªºì¦]¡C¦b 1 ´Á¸ÕÅ礤¡A600 ²@§J¾¯¶qªº ASLAN004 Åã¥Ü¥Ö½§²M°£²v¦³ 65% ªº²Îp¾ÇÅãµÛÅܤƱq²Ä 8 ¶gªº°ò½u¶}©l¡CµM¦Ó¡A¦³¤H¾á¤ß±q³Ìªìªº·N¦VªvÀø¤H¸s¤¤¥h°£ 9 ¦W±wªÌ¡A¥H¤Î¨Ï¥Î³æ¤è± p Ȫº¬ã¨s¡C¤]³\§ó¥O¤H¾á¼~ªº¬O¡A¹F¨ì 0/1 ªº IGA µû¤À¡]§Y³z©ú©Î´X¥G³z©úªº¥Ö½§¡^ªº±wªÌ¼Æ¶q¨Ã¤£ÅãµÛ¡A¬° 48.3%¡A¦Ó¦w¼¢¾¯¬° 15.4%¡]p=0.107¡^¡F³o«Ü«n¡A¦]¬° IGA 0/1 ¤À¼Æ¥Î©ó¬ü°ê§åã¡C¥i¥H»¡¡A¼Ë¥»¶q¬° 29¡X¡X±q 38 ´î¤Ö¡X¡XµLªkÅã¥Ü¥X©ú½Tªºµ²ªG¡A¦ýµ²ªG¦ü¥G¤]Åã¥Ü¥X¥\®Ä°§C¡F3 ¤ë¡A22% ªº±wªÌ¹F¨ì IGA ©Î 0/1¡A¦Ó¦w¼¢¾¯²Õ¬° 0%¡Cªü´µÄõ§Æ±æ¦b¦~©³«e¶}©l¤@¶µ 2 ´Á¸ÕÅç¡A¤@Ó¾á¼~¬O Àø®Ä¦ü¥G¥¿¦b´î®z ¥i¯à·|¦]§ó¤jªº¼Æ¦r¦Ó¥[¼@¡C
Aslan fails to roar with atopic dermatitis data • Dupixent has set such a high bar in atopic dermatitis anyone coming for its crown had better come prepared. This could be why questions around Aslan Pharmaceuticals¡¦ trial design and results contributed to a 31% fall in the group¡¦s share price. In the phase 1 trial a 600mg dose of ASLAN004 showed a statistically significant 65% change in skin clearance from baseline at week 8. However, there were concerns about the removal of nine patients from the original intent-to-treat population and the study using a one-sided p value. Perhaps more worrying was that the number of patients achieving a IGA score of 0/1, ie clear or almost clear skin, was not significant at 48.3% versus 15.4% for placebo (p=0.107); this is important as the IGA 0/1 score is used for US approval. Arguably the sample size of 29 ¡V reduced from 38 ¡V was not powered to show a definitive result, but the result also appeared to show reduced efficacy; in March 22% of patients achieved IGA or 0/1, compared with 0% on placebo. Aslan is looking to begin a phase 2 trial before the end of the year and one concern is that what looks like waning efficacy could be exacerbated with larger numbers.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/28 ¤W¤È 12:15:21
²Ä 4517 ½g¦^À³
|
¤@´Á¨S¦³¦¨¥\¥¢±Ñªº°ÝÃD , £¸´ÁÁ{§É¦b¬Ý¦w¥þ©Ê@¨ü©Ê»PÀø®Ä¼ç¤O¡A²¦³º¥uÆ[¹î¤K¶g¡A¤£¬O¤Q¤»¶g¡A¬ã¨s¹Î¶¤·|¨Ì¾Ú£¸´Á¼Æ¾Ú¨Óµû¦ô¤Gb¦¨¥\¾÷²v
ASLAN Pharmaceuticals º®uÂåÀø©x Ken Kobayashi ³Õ¤hµû½×»¡¡G¡§§ÚÌ«Ü°ª¿³³ø§iÃö©ó ASLAN004 ªº¦p¦¹¿n·¥ªº¼Æ¾Ú¡C ¸Ó¬ã¨sªº¼Æ¾Ú§¹¥þ¤ä«ù§Ú̪ºÆ[ÂI¡A§Y ASLAN004 ªº·s¾÷¨î¥i¥H¥Nªí¤¤«×¦Ü««× AD ±wªÌªº·sªvÀø¿ï¾Ü¡A¦³¥i¯à´£¨Ñ¤@¬yªºÀø®Ä©M¤@¬yªº¦w¥þ©Ê¡C§ÚÌ´Á«Ý¦b¥¼¨Ó´X©P§Q¥Î³o¤@±j¤jªº¼Æ¾Ú±Ò°Ê 2b ´Á¬ã¨s¨Ã±´¯Á¥i¥H¬°±wªÌ´£¨ÑÃB¥~«K§Qªº¨C¤ëµ¹ÃĤè®×
¤º¦æªº¤½¥q°ª¼h¤µ¤Ñ«Ü¿³¾Ä,©ñ¤¤½u³¨¤j³½¤w¦b¥¢¥h²z´¼¤¤´²¤á¶Ã±þ¤@³q, ¤µ¤ÑÄw½X¤w¸g³Q¦³¤ß¤H»´©ö¦¬¨«
ASLAN004 ªº·s¾÷¨î¥i¥H¥Nªí¤¤«×¦Ü««× AD ±wªÌªº·sªvÀø¿ï¾Ü¡A¦³¥i¯à´£¨Ñ¤@¬yªºÀø®Ä©M¤@¬yªº¦w¥þ©Ê¡C§ÚÌ´Á«Ý¦b¥¼¨Ó´X©P§Q¥Î³o¤@±j¤jªº¼Æ¾Ú±Ò°Ê2b´Á¬ã¨s¨Ã±´¯Á¥i¥H¬°±wªÌ´£¨ÑÃB¥~«K§Qªº¨C¤ëµ¹ÃĤè®×
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§ë¸ê¬ö«ß10145266 |
µoªí®É¶¡:2021/9/28 ¤W¤È 12:03:21
²Ä 4516 ½g¦^À³
|
¸Ñª¼¦¨¥\¡A¦ý¥«³õ²@¤£¯d±¡ªº±þ
¬O¦³¤°»ò¤j®a¬Ý¤£¨ìªº±¦V¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/27 ¤U¤È 11:54:18
²Ä 4515 ½g¦^À³
|
ASLAN004 2bÁ{§É¥l¶Ò300¤H ¤H¼ÆÂX¤jPȤ]¸û©ö¹F¼Ð¦Ó¥Bº}«G¡ADupilumab ¤T´ÁEASI75 ¹êÅç²Õ44%-52% ¹ï·Ó²Õ12%-15% IGA 0\1 ¹êÅç²Õ36%-38% ¹ï·Ó²Õ8%-10% pÈ«D±`º}«G¡A
ASLAN £¸´Á EASI75 ¹êÅç²Õ RITT 8¶g 600mg 69% ¹ï·Ó²Õ15% pÈ 0.005
ITT ¹êÅç²Õ 50%
¹ï·Ó²Õ15% pÈ0.018
IGA 0\1 RITT ¹êÅç²Õ44% ¹ï·Ó²Õ15%
ITT ¹êÅç²Õ32% ¹ï·Ó²Õ19%
¦pÆ[¹î¨ì16¶g¤H¼Æ¼W¦hpÈ·|§óº}«G¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/27 ¤U¤È 11:25:42
²Ä 4514 ½g¦^À³
|
°ò¥»¤W¯}2¤¸¾÷²v¤£°ª¤F~¤j®a¦n¦n§â´¤¤µ¤Ñªº¾÷·| ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/27 ¤U¤È 11:18:45
²Ä 4513 ½g¦^À³
|
§AÌþ¨Óªº«i®ðÁÙ´±¦A¥[½X ¨ØªA§AÌ §Ú¤w¸g©È¨ì¤F¡A¸Ñª¼¹LÁÙ¯à¤j¶^ ¥u¯àµL»y°Ý»a¤Ñ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/9/27 ¤U¤È 11:17:10
²Ä 4512 ½g¦^À³
|
¥[½X¥[¨ì¨S¿ú¡A¦¨¥»ÁÙ¦b3.5...
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/27 ¤U¤È 11:14:47
²Ä 4511 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 11:13:02
²Ä 4510 ½g¦^À³
|
±À½×: ¦b°ò½u©Ô¥«á
ASLAN004 ¦b¤T´Á¥Dn«ü¼ÐEASI75 ¤´¦³30%~34% ªºIGA 4 ÄY«±wªÌ¹F¼Ð, Àu©óDUPILUMAB (¤T´Á±À¦ô)¥i¯àµL¥ô¦ó¤H¹F¼Ðªº¼ç¤O, ¨âÃĦb°ò½uIGA 3 ,¤¤«×±wªÌªvÀø«á¹F¼Ð¤ñ²v«h¬Û·í.
¥H¤Wµ²±À½×¦P3¤ë1¤éªº³ø§i±À½×没ÅÜ.
------------------- ¤@.ASLAN004 (8¶gªvÀø)EASI-75 69% (BASE LINE IGA 3/4 =56%/44%),
¥Nªí °ò½uIGA 3±wªÌ, 100%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
¥Nªí °ò½uIGA 4±wªÌ, 13%/44%=30%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
**********
¤G.Dupilumab ¤T´Á (16¶gªvÀø)EASI-75 50% (BASE LINE IGA 3/4 =52%/48%),
¥Nªí °ò½uIGA 3±wªÌ, 5%0/52%=96%¥i¹F¦¨¤T´Á«ü¼ÐEASI75
¥Nªí °ò½uIGA 4±wªÌ, 0%/48%=0% ,µL¤H¥i¹F¦¨¤T´Á«ü¼ÐEASI75
---------------------------------------------------------- P.27
¤ñ¸û¤FASLAN004(8¶g )©MDUPILUMAB(16¶g) ¤T´Á¥Dn«ü¼Ð EASI75¤ÎIGA 0/1 ,
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
----------------------------------
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/27 ¤U¤È 11:03:13
²Ä 4509 ½g¦^À³
|
£¸´ÁÁ{§É¦b¬Ý¦w¥þ©Ê@¨ü©Ê»PÀø®Ä¼ç¤O¡A²¦³º¥uÆ[¹î¤K¶g¡A¤£¬O¤Q¤»¶g¡A¬ã¨s¹Î¶¤·|¨Ì¾Ú£¸´Á¼Æ¾Ú¨Óµû¦ô¤Gb¦¨¥\¾÷²v
In the RITT population, the average reduction from baseline in EASI at 8 weeks was 65% (n=16) compared to 27% (n=13) for patients on placebo (p=0.0211).
•69% achieved EASI-75 versus 15% on placebo (p=0.0051)
¤ñ¸û¤FASLAN004(8YBGR )©MDUPILUMAB(16¶g) ¤T´Á¥Dn«ü¼Ð EASI75¤ÎIGA 0/1 ,
IGA 4= 44% ,§ó±µªñDUPILUMAB 亖´Á475~49%. ½Õ¾ã°ò½u«áASLAN004¦bESAI 75¤´Àu©óDUPILUMAB ¤T´Á, ¦ý¦bIGA 0.1,¨âªÌ®t¤£¦hªº®ÄªG,¦ýASLAN004 ¥¼¨Ó16¶gªºªvÀø¤´¦³©Ô¶}Àu¶Õ.
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
Æ[¹î«ÂI:¦³Æ[¹î¨ìASLAN004 ªº¼ç¤O ¤~´±¦b2B Á{§É¦³¦p¤U³]p (¨C¤G¶g¤@°w , «z! ÁÙ´±¥Î4¶g¤@°w) 1 300mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3000mg 2 400mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3600mg
3.400mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3000mg 4.600mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3600mg 5 ¹ï·Ó²Õ
¤À¤²Õ¦@¦¬300¤H*16¶gªvÀø
1.300mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3000mg 2.400mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3600mg 3.400mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3000mg 4.600mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3600mg 5.¹ï·Ó²Õ
¤j®a¥h¬Ý3¤ëªì ²³ø lebrikizumab 4¶g 8¶g 16¶g ®t²§ ¨ì16¶gªºªvÀø¦³©Ô¶}Àu¶Õ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/27 ¤U¤È 10:55:41
²Ä 4508 ½g¦^À³
|
¬Ý¹L²³ø¼Æ¾Ú¡A§Ú¤£ª¾¹D¬°¤°»ò·|³o¼Ë¶^... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gyang10150461 |
µoªí®É¶¡:2021/9/27 ¤U¤È 10:55:14
²Ä 4507 ½g¦^À³
|
¦M¾÷¤J¥«,¥[½X(½Ð¦Û¦æ¿ìÂ_) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/27 ¤U¤È 10:51:44
²Ä 4506 ½g¦^À³
|
2.3»ù¦ì¬O¤@Ó¦n¶RÂI~¦³¤ä¼µ©Ê~¤µ¤Ñ¶X§C³{§C¶R¤J!!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/9/27 ¤U¤È 10:36:38
²Ä 4505 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/9/27 ¤U¤È 10:21:43
²Ä 4504 ½g¦^À³
|
¨È·à±d¸Ñª¼¥¢±ÑªÑ»ù¤j¶^ ¸Ñª¼¦¨¥\ªÑ»ù¤´¤j¶^ ¶^¨ì¤£ª¾©Ò±¹ÃhºÃ¤H¥Í |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 10:16:09
²Ä 4503 ½g¦^À³
|
°ò½u ,P.15 RITT Patients with IGA 3 / IGA 4 =56%/44%
3¤ë1¤é ³ø§i
Patients with IGA 3 / IGA 4 =67%(6/9)/33%(3/9)----(600mg+400mg ²Õ9¦ì)
©Ò¥H¥»¦¸Á{§É©Û¶Ò¹ï¶H¤ñ3¤ë1¤é³ø§i,¦b°ò½uIGA 4 ¼W¥[11%,§óÄY«ªº±wªÌ.
---------------------------------------------------------- P.27
¤ñ¸û¤FASLAN004(8YBGR )©MDUPILUMAB(16¶g) ¤T´Á¥Dn«ü¼Ð EASI75¤ÎIGA 0/1 ,
IGA 4= 44% ,§ó±µªñDUPILUMAB 亖´Á475~49%. ½Õ¾ã°ò½u«áASLAN004¦bESAI 75¤´Àu©óDUPILUMAB ¤T´Á, ¦ý¦bIGA 0.1,¨âªÌ®t¤£¦hªº®ÄªG,¦ýASLAN004 ¥¼¨Ó16¶gªºªvÀø¤´¦³©Ô¶}Àu¶Õ.
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/9/27 ¤U¤È 10:12:19
²Ä 4502 ½g¦^À³
|
¶â...Á`·Pı®×±¡¤£³æ¯Â ¦³¤H¦b¦Y§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/9/27 ¤U¤È 09:54:22
²Ä 4501 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¾ð10027223 |
µoªí®É¶¡:2021/9/27 ¤U¤È 09:52:08
²Ä 4500 ½g¦^À³
|
¯u°²Ãø¿ë¡B¦nÃa°Ñ¥bªº¼Æ¾Ú¡I ¬~¸£ªº¸ê°T³]§½ªº°ª¤â¡A¾Þ§@nÂÔ·V³B²z¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 09:49:37
²Ä 4499 ½g¦^À³
|
ASLAN004 2b Á{§É³]p¥X²{
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
³Ì·s¤½¥q³ø§i
p.26
¤À¤²Õ¦@¦¬300¤H*16¶gªvÀø
1.300mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3000mg 2.400mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3600mg 3.400mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3000mg 4.600mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3600mg 5.¹ï·Ó²Õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 09:24:39
²Ä 4498 ½g¦^À³
|
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
³Ì·s¤½¥q³ø§i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:59:48
²Ä 4497 ½g¦^À³
|
¤j®a³£Ä±±o¼Æ¾Ú¤£¿ù¶Ü¡H ¨º½L«e¬O¶^¤°»òªº¡K ü¡A§Ú«Ü«ùªÑ¡A¤µ¤Ñn¶^±¼¤@³¡¨®¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:52:52
²Ä 4496 ½g¦^À³
|
Dupilumab ¦U´ÁÁ{§É¼Æ¾Ú¡C
1. Dupilumab ¦´Á¥|Ó AD Á{§É 4¶g/12¶g , 2014/07/10
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
www.nejm.org/doi/10.1056/NEJMoa1314768
2. Dupilumab 2a/2b Á{§É ,2018/SEP
journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx
3.Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:36:57
²Ä 4495 ½g¦^À³
|
ASLAN»sÃĤ½¥qº®uÂåÀø©xKen Kobayashi³Õ¤h»¡¡C
¡§§Úַ̫ܼN³ø§iASLAN004ªº¦p¦¹¥¿¦Vªº¼Æ¾Ú¡C
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ ¸Ó¬ã¨sªº¼Æ¾Ú§¹¥þ¤ä«ù§Ú̪ºÆ[ÂI¡A§Y ASLAN004 ªº·s¾÷¨î¥i¥H¥Nªí¤¤«×¦Ü««× AD ±wªÌªº·sªvÀø¿ï¾Ü¡A
¦³¥i¯à´£¨Ñ¦P³Ì¨ÎªºÀø®Ä(best-in-class efficacy)©M¦P¯Å³Ì¨Îªº¦w¥þ©Ê¡C( best-in-class safety.) @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ §ÚÌ´Á«Ý¦b¥¼¨Ó´X©P±Ò°Ê 2b ´Á¬ã¨s¨Ã±´¯Á¥i¥H¬°±wªÌ´£¨ÑÃB¥~«K§Qªº¨C¤ëµ¹ÃĤè®×®É¡A§Q¥Î³o¤@±j¤jªº¼Æ¾Ú¶°¡C¡¨
Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: ¡§We¡¦re delighted to report such positive data on ASLAN004. The data from the study wholly support our view that ASLAN004¡¦s novel mechanism could represent a new treatment option for patients suffering with moderate-to-severe AD, with the potential to deliver best-in-class efficacy and best-in-class safety. We look forward to building upon this strong data set as we initiate the Phase 2b study in the coming weeks and explore monthly dosing regimens that could provide additional convenience to patients.¡¨
finance.yahoo.com/news/aslan-pharmaceuticals-announces-positive-data-100000377.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcheers10152291 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:36:17
²Ä 4494 ½g¦^À³
|
èÅ¥§¹conference¡Aµ¥µ¥¶}½L¾ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:30:11
²Ä 4493 ½g¦^À³
|
®z®zªº°Ý ³oӼƾڦ³¶W¶V1.Dupliumabªº¼ç¤O¶Ü¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:21:37
²Ä 4492 ½g¦^À³
|
2013¦~ dupilumab 1b ·§©À©ÊÁ{§É¦¨¥\³ø¾É
www.europeanpharmaceuticalreview.com/news/17492/sanofi-and-regeneron-report-positive-proof-of-concept-data-for-dupilumab/
Sanofi and Regeneron report positive proof-of-concept data for Dupilumab Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other exploratory endpoints included pharmacokinetic, biomarker, and efficacy parameters. The efficacy data showed that treatment with four weekly subcutaneous injections of dupilumab at either 150 milligrams (mg) or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis (AD) whose disease was not adequately controlled with topical medications. Specifically, patients treated with dupilumab had significant improvements in body surface area (BSA) score, Investigator Global Assessment (IGA) score, and Eczema Area Severity Index (EASI) from baseline to week 4 compared to placebo (p<0.05 vs. placebo for all measures and doses). The significant improvements in BSA, IGA, and EASI scores were maintained at week 8 in the 300mg dose group (p<0.05 vs. placebo). A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05). The most common adverse events (AEs) were nasopharyngitis (19.6% vs. 12.5% for placebo) and headache (11.8% vs. 6.3% for placebo).
¡§Despite existing therapies, a significant proportion of patients with moderate-to-severe atopic dermatitis continue to suffer from inflamed skin and intractable itch, which significantly impacts their quality of life,¡¨ said Dr. Eric Simpson, Associate Professor, Director of Clinical Studies, Oregon Health and Science University, Portland, Oregon, USA, and Principal Investigator of the study. ¡§The early phase results with this biologic therapy, which has a novel mechanism of action, are encouraging to those of us who treat these patients and warrant further clinical investigation.¡¨
¡§Through blockade of the IL-4alpha receptor, dupilumab modulates signaling of both the IL-4 and IL- 13 pathway, which have been implicated in the pathophysiology of allergic disease,¡¨ said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. ¡§We look forward to presenting additional data from a 12-week, Phase 2a trial in atopic dermatitis, as well as starting a larger Phase 2b trial with dupilumab in patients with atopic dermatitis, later this year.¡¨
Presented today in a late-breaking clinical trials session at the AAD meeting, the Phase 1b trials included 67 patients randomized to three different doses of dupilumab (75mg, n=8; 150mg, n=22; 300mg, n=21) and placebo (n=16). The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other endpoints included pharmacokinetic, biomarker, and efficacy parameters. Following the 4-week treatment period, patients in the studies were followed for an additional 4 weeks for a total of 8 weeks. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:10:14
²Ä 4491 ½g¦^À³
|
- ASLAN004¹F¨ì²Îp¾ÇÅãµÛ§ïµ½¡]p <0.025 1¦bEASI»P¦w¼¢¾¯¡^¦b¦Ê¤À¤ñÅܤƪº¥DnÀø®Ä²×ÂI±q°ò½u»P¨ä¥L¥\®Ä²×ÂIÅãµÛ§ï¶i
-¨}¦nªº@¨ü©Ê»P¦b¿±µÈ¶¤¦Cµ²½¤ª¢¨S¦³¨Ò
-¦by¹D±N¦b 21¦~²Ä¥|©u«×©Û¶Ò²Ä¤@¦W±wªÌ°Ñ¥[¥þ²y 2b ´Á¬ã¨s- ºÞ²z¼h±N©ó
¤µ¤Ñ¡]9 ¤ë 27 ¤é¡^ªF³¡®É¶¡¤W¤È 8 ÂI/·s¥[©Y¼Ð·Ç®É¶¡±ß¤W 8 ÂI¥D«ù¹q¸Ü·|ij©Mºôµ¸ª½¼½
¥[§QºÖ¥§¨È¦{ªù¬¥©¬§J©M·s¥[©Y¡A2021 ¦~ 9 ¤ë 27 ¤é¡]Àô²y·s»DªÀ¡^--ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¿n·¥¨Ó¦Û¨äÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B8 ¶g¡B¦h¦¸»¼¼W¾¯¶q (MAD) 1 ´Á¬ã¨s ASLAN004 ªvÀø¤¤««×¯SÀ³©Ê¥Öª¢ (AD) ªº¤@½u¼Æ¾Ú¡CASLAN004 ¬O¤@ºØ¼ç¦bªº¤@¬y³æ§J¶©§ÜÅé¡A¹v¦V IL-13 ¨üÅé¡A¦b©Ò¦³¾¯¶q¤U§¡Åã¥Ü¥X¨}¦nªº@¨ü©Ê¡C¸Ó¬ã¨sªº¼Æ¾Ú³Ì²×½T¥ß¤F·§©ÀÃÒ©ú¡A¨Ã¤ä«ù ASLAN004 §@¬° AD ªº®t²§¤Æ·s«¬ªvÀø¤èªkªº¼ç¤O¡C
2021 ¦~ 3 ¤ë¡AASLAN ¤½§G¤F¤TÓ¾¯¶q»¼¼W¶¤¦Cªº¤¤´Á¼Æ¾Ú¡AµM«áÄ~Äò¥H³Ì°ª¾¯¶q¡]600mg¡^¦bÂX®i¶¤¦C¤¤©Û¶Ò©MªvÀø¥t¥~ 27 ¦W±wªÌ¡C¤µ¤Ñ¤½§Gªºµ²ªG¤ñ¸û¤F©Ò¦³±µ¨ü 600mg ªº±wªÌ»P©Ò¦³±µ¨ü¦w¼¢¾¯ªº±wªÌ¡]n=39¡^ªºµ²ªG¡C·N¦VªvÀø (ITT) ¤H¸s¡]n=38¡^¥Ñ¨Ó¦Û 10 Ó¦aÂIªº±wªÌ²Õ¦¨¡A¥Nªí©Ò¦³±µ¨üµ¹ÃĪº±wªÌ¡A¤£¥]¬A¤@¦W¦] COVID-19 »s¦Ó´£«e°h¥X¬ã¨sªº±wªÌ¡C
»P¦w¼¢¾¯¬Û¤ñ¡AASLAN004¦bÀã¯l±¿nÄY«µ{«×«ü¼Æ (EASI) ¬Û¹ï©ó°ò½uªº¦Ê¤À¤ñÅܤƪº¥DnÀø®Ä²×ÂI¤è±¨ú±o¤F²Îp¾ÇÅãµÛ§ïµ½ (p<0.025 1 )¡A¨Ã¥B¦b¨ä¥LÃöÁäÀø®Ä²×ÂI¤è±¤]ªí²{¥XÅãµÛ§ïµ½ (p<0.05 1 ) ¡GEASI-50¡BEASI-75¡B®pÈæ±Äo©M¥H±wªÌ¬°¾É¦VªºÀã¯l±¹¬I (POEM)¡C
¦b´¦ª¼«e»P¼Æ¾ÚºÊ´ú©eû·|°Q½×«á¡A×qªº ITT ¤H¸s¡]RITT¡An = 29¡^³Q©w¸q¬°±Æ°£¤@Ó¬ã¨s¦aÂI¡A¦b¸Ó¬ã¨s¦aÂI¡A®Ú¾Ú¥Íª«¼Ð»xª«¡A©Ò¦³°Ñ¥[¬ã¨sªº±wªÌ³£ªí²{¥X«D¨å«¬ªº¤¤«×¦Ü««× AD ±wªÌ¡A¨Ò¦p TARC ©M±wªÌ¯f¥v2¡C¦b RITT ¤H¸s¤¤¡A»P¨ä¥L¤wµoªíªº¤¤«×¦Ü««× AD¬ã¨s3§ó¨ã¥i¤ñ©Ê¡AASLAN004»P¦w¼¢¾¯¬Û¤ñ¡A¦b EASI »P°ò½u¬Û¤ñªº¦Ê¤À¤ñÅܤƤ豤]¨ú±o¤F²Îp¾Ç¤WªºÅãµÛ§ïµ½¡]p<0.025 1¡^¡A¨Ã¥BÅã¥Ü¥X¤ñ¦w¼¢¾¯§ó¤jªº§ïµ½¦w¼¢¾¯¦bÃöÁäÀø®Ä²×ÂI»P ITT ¤H¸s¬Û¤ñ¡C
¥Dn¬ã¨sµ²ªG
¦b RITT ¤H¸s¤¤¡A8 ¶g®É EASI ªº¥§¡°§C²v¬° 65% (n=16)¡A¦Ó¦w¼¢¾¯²Õ¬° 27% (n=13) (p=0.021 1 )¡C 69% ¹F¨ì EASI-75¡A¦Ó¦w¼¢¾¯²Õ¬° 15% (p=0.005 1 )¡F 44% ªº±wªÌ¹F¨ì 0 ©Î 1 ªº¬ã¨sªÌÁ`Åéµû¦ô (IGA)¡A¦Ó¦w¼¢¾¯²Õ¬° 15% (p=0.107 1 )¡C ¦b©Ò¦³¯¸ÂI§¹¦¨¦Ü¤Ö 29 ¤Ñµ¹ÃĪº 32 ¦W±wªÌ¤¤¡A¦b¨óij¤¤©w¸q¬°Àø®Ä¥iµû¦ô¼Æ¾Ú¶°¡A8 ¶g®É EASI ±q°ò½uªº¥§¡°§C²v¬° 73%¡]n=19¡^¡A¦Ó 44%¡] n=13¡^¹ï©ó±µ¨ü¦w¼¢¾¯ªº±wªÌ¡]p=0.007 1¡^¡C ¥X²{¤£¨}¨Æ¥ó©MªvÀø¬ÛÃö¤£¨}¨Æ¥óªº±wªÌ¤ñ¨Ò¦bªvÀø²Õ©M¦w¼¢¾¯²Õ¤¤¬Û¦ü¡C¦bÂX®i¶¤¦C¤¤¨S¦³µ²½¤ª¢ªºµo¥Í²v¡C
²×ÂI¡]8 ¶g¡^
¨½¯S (n=29) ITT (n=38) 600mg (n=16) ¦w¼¢¾¯ (n=13) p È1 600mg (n=22) ¦w¼¢¾¯ (n=16) p È1 EASI ±q°ò½uªº¥§¡ÅܤƦʤÀ¤ñ -64.9 -27.2 0.021 -61.3 -31.9 0.023 EASI-50 (%) 81.3 30.8 0.008 77.3 37.5 0.016 EASI-75 (%) 68.8 15.4 0.005 50.0 12.5 0.018 EASI-90 (%) 37.5 15.4 0.183 27.3 12.5 0.245 IGA 0/1 (%) 43.8 15.4 0.107 31.8 18.8 0.301 ®pÈæ±Äo ¼Æȵû©w¶qªí¬Û¹ï©ó°ò½uªº¥§¡ÅܤƦʤÀ¤ñ -38.6 -15.3 0.051 -37.1 -15.7 0.032 POEM ¤¤°ò½uªº¥§¡ÅÜ¤Æ -9.8 -2.5 0.007 -9.0 -3.5 0.014 ASLAN Pharmaceuticals º®uÂåÀø©x Ken Kobayashi ³Õ¤hµû½×»¡¡G ¡§§ÚÌ«Ü°ª¿³³ø§iÃö©ó ASLAN004 ªº¦p¦¹¿n·¥ªº¼Æ¾Ú¡C¸Ó¬ã¨sªº¼Æ¾Ú§¹¥þ¤ä«ù§Ú̪ºÆ[ÂI¡A§Y ASLAN004 ªº·s¾÷¨î¥i¥H¥Nªí¤¤«×¦Ü««× AD ±wªÌªº·sªvÀø¿ï¾Ü¡A¦³¥i¯à´£¨Ñ¤@¬yªºÀø®Ä©M¤@¬yªº¦w¥þ©Ê¡C§ÚÌ´Á«Ý¦b¥¼¨Ó´X©P±Ò°Ê 2b ´Á¬ã¨s¨Ã±´¯Á¥i¥H¬°±wªÌ´£¨ÑÃB¥~«K§Qªº¨C¤ëµ¹ÃĤè®×®É¡A§Q¥Î³o¤@±j¤jªº¼Æ¾Ú¶°¡C¡¨
º®u¬ã¨sû Steven Thng ³Õ¤h»¡¡G¡§¯SÀ³©Ê¥Öª¢¬O¥@¬É½d³ò¤º³Ì±`¨£ªº¥Ö½§¯f¤§¤@¡A¨Ã§e²{¥X¤@¨t¦C¹ï±wªÌ¥Í¬¡½è¶q²£¥Í¥¨¤jt±¼vÅTªº¯gª¬¡C±wªÌ¡A¤×¨ä¬O¤¤«×¦Ü««×¯e¯f±wªÌ¡A¤´µM«D±`»Ýn¦w¥þ¡B¦³®Ä¥B¨Ï¥Î¤è«Kªº·s«¬ªvÀø¤è®×¡A¥H§JªA¥Ø«e¥i¨Ñ¥LÌ¿ï¾Üªº¤è®×ªº§½©Ê¡C¬ã¨sµ²ªGªí©ú¡AASLAN004 ¥i¥H¬°±wªÌ´£¨Ñ´X¥G§¹¥þ²M¼äªº¥Ö½§©M´î»´¤é±`¥Í¬¡¤¤¯SÀ³©Ê¥Öª¢t¾áªº¼ç¦b¯q³B¡C¡¨
ASLAN ¥¿¦b±Ò°Ê ASLAN004 ªvÀø AD ªº¥þ²y 2b ´Á¬ã¨s¡A¨Ã¦³±æ¦b 2021 ¦~²Ä¥|©u«×©Û¶Ò²Ä¤@¦W±wªÌ¡CASLAN ±N©ó 2021 ¦~²Ä¥|©u«×¦b AD ¬°§ë¸êªÌÁ|¿ìÃö©ó ASLAN004 ªº KOL ¬¡°Ê¡C¨Ó¦Û MAD ªº§¹¾ã¼Æ¾Ú¬ã¨s±N´£¥æµ¹¥¼¨Óªº¬ì¾Ç¤j·|¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 08:06:54
²Ä 4490 ½g¦^À³
|
ASLAN004 ·§©À©ÊÁ{§É¸Ñª¼¦¨¥\------¶È¦¹¤¤-««×AD³Q¨Ö»ùÈ22»õ¬ü¤¸(°Ñ¦ÒLebrikizamab)
ASLAN Pharmaceuticals «Å¥¬¥¿¦V¼Æ¾Ú¡A³Ì²×½T¥ß¤F ASLAN004ªvÀø¯SÀ³©Ê¥Öª¢ªº·§©ÀÃÒ©ú
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
»P¦w¼¢¾¯¬Û¤ñ¡AASLAN004 ¦b EASI ¬Û¹ï©ó°ò½uªº¦Ê¤À¤ñÅܤƪº¥DnÀø®Ä²×ÂI¤è±¨ú±o¤F²Îp¾Ç¤WªºÅãµÛ§ïµ½¡]p<0.0251¡^¡A¨Ã¦b¨ä¥LÀø®Ä²×ÂI¤è±¨ú±o¤FÅãµÛ§ïµ½
ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints
finance.yahoo.com/news/aslan-pharmaceuticals-announces-positive-data-100000377.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2021/9/27 ¤U¤È 07:59:44
²Ä 4489 ½g¦^À³
|
Aslan Pharmaceuticals Inc. ¶g¤@ªí¥Ü¡A¨ä ASLAN004 ¹êÅçÃĪ«¦b´ú¸Õ¨ä¦b¯SÀ³©Ê¥Öª¢¤¤ªº¨Ï¥Îªº²Ä¤@¶¥¬q¬ã¨s¤¤Åã¥Ü¥X¿n·¥ªºµ²ªG¡C
¸Ó¬ã¨sªºµ²ªG¥]¬A¨Ï¥Î 600 ²@§J¾¯¶qªº³æ§J¶©§ÜÅéÃĪ«ªº¼Æ¾Ú¡CÁ`³¡¦ì©ó¥[§QºÖ¥§¨È¦{ªù¬¥©¬§Jªºªü´µÄõ»¡¡A¸ÓÃĪ«¦b¥Dn²×ÂI¡]Àã¯l°Ï°ìÄY«µ{«×«ü¼Æ»P°ò½u¬Û¤ñªº¦Ê¤À¤ñÅܤơ^¤è±¨ú±o¤F²Îp¾Ç¤WªºÅãµÛ§ïµ½¡C
¸Ó¤½¥qªí¥Ü¡A¸ÓÃĪ«¥Î©óªvÀø¯SÀ³©Ê¥Öª¢ªº 2b ´Á¬ã¨s±N¦b¤µ¦~²Ä¥|©u«×©Û¶Ò¨ä²Ä¤@¦ì±wªÌ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 07:45:07
²Ä 4488 ½g¦^À³
|
1.Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð(2016¦~¤½¥¬)
°ò½uIGA,0/1 3:4 50%:50% ,¥§¡EASI 32
(¤@).300 mg Q2W(¨â¶g¤@°w/16¶g) EASI-50 65%/69% EASI-75 51%/44% EASI-90 36%/30% IGA0/1 38%/36%
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%
2.Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
°ò½uIGA,0/1 3:4 29%:71% ,¥§¡EASI 25.5
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
(¤G).250 mg Q4W(¥|¶g¤@°w) EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/27 ¤U¤È 07:23:20
²Ä 4487 ½g¦^À³
|
JCY ¤j,
¥»¦¸¤ñ²v¬O ITT(N=38 ,22:16) RITT(N=29,16:13)
¬G¤ñ²v¬Ý°_¨Ó¤ñ3¤ë1¤é®t.¬°ì¦]¤§¤@, °ò½u©|¤£ª¾,µ¥§ó¸Ô²Ó¸ê®Æ¥X¨Ó¦A°µ¤ñ¸û.
ESAI-75 68.8% VS. 15.4%, P=0.005 «D±`¦nªº¼Æ¾Ú(RITT). ESAI-75 50.0 VS. 12.5%, P=0.018 «D±`¦nªº¼Æ¾Ú(ITT). Investigator¡¦s Global Assessment (IGA) of 0 or 1 43.8% versus 15.4% on placebo (p=0.1071). -----·í2b ©ñ¤j¨ìN=55:55, P=0.0011
¥H¤W¬°2b ¤Î¤T´ÁÁ{§É¥Dn«ü¼Ð.
2b ¬O16¶gªºªvÀø,¥Ø«e¶È8¶g. ¥¼¨ÓEASI90¤ÎIGA 0/1 ·|¦A¤j´T¼W¥[.
n the RITT population, the average reduction from baseline in EASI at 8 weeks was 65% (n=16) compared to 27% (n=13) for patients on placebo (p=0.0211).
69% achieved EASI-75 versus 15% on placebo (p=0.0051);
44% of patients achieved Investigator¡¦s Global Assessment (IGA) of 0 or 1 versus 15% on placebo (p=0.1071).
ASLAN»sÃĤ½¥qº®uÂåÀø©xKen Kobayashi³Õ¤h»¡¡C¡§§Úַ̫ܼN³ø§iASLAN004ªº¦p¦¹¿n·¥ªº¼Æ¾Ú¡C
¸Ó¬ã¨sªº¼Æ¾Ú§¹¥þ¤ä«ù§Ú̪ºÆ[ÂI¡AASLAN004ªº·s¾÷¨î§Y¥i¥H¬°¤¤«×¦Ü««×AD±wªÌ´£¨Ñ·sªº ªºªvÀø¡A
¸Ó¬ã¨sªº¼Æ¾Ú§¹¥þ¤ä«ù§Ú̪ºÆ[ÂI¡A§Y ASLAN004 ªº·s¾÷¨î¥i¥H¥Nªí¤¤«×¦Ü««× AD ±wªÌªº·sªvÀø¿ï¾Ü¡A¦³¥i¯à´£¨Ñ¦P³Ì¨ÎªºÀø®Ä(best-in-class efficacy)©M¦P¯Å³Ì¨Îªº¦w¥þ©Ê¡C( best-in-class safety.)
§ÚÌ´Á«Ý¦b¥¼¨Ó´X©P±Ò°Ê 2b ´Á¬ã¨s¨Ã±´¯Á¥i¥H¬°±wªÌ´£¨ÑÃB¥~«K§Qªº¨C¤ëµ¹ÃĤè®×®É¡A§Q¥Î³o¤@±j¤jªº¼Æ¾Ú¶°¡C¡¨
Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: ¡§We¡¦re delighted to report such positive data on ASLAN004. The data from the study wholly support our view that ASLAN004¡¦s novel mechanism could represent a new treatment option for patients suffering with moderate-to-severe AD, with the potential to deliver best-in-class efficacy and best-in-class safety. We look forward to building upon this strong data set as we initiate the Phase 2b study in the coming weeks and explore monthly dosing regimens that could provide additional convenience to patients.¡¨ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/9/27 ¤U¤È 07:13:48
²Ä 4486 ½g¦^À³
|
¼Æ¾Ú¤£¦p¹O´Á¦Ó¥BÁÙ¬O1´Á~¹Ú°µ§¹¤F~¤j®a¥i¥H¿ô¤F !! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/27 ¤U¤È 07:07:09
²Ä 4485 ½g¦^À³
|
½L«e¤j¶^¤¤¡A¬Ý¨Ó¬O¤£²Å¹w´Á |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/9/27 ¤U¤È 07:03:10
²Ä 4484 ½g¦^À³
|
¤Ñ©R¤j¡A±z«ç»ò¬ÝEASI-90¤ÎIGA0/1ªº³¡¥÷¡H |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 2101 ~ 2200 «h¦^ÂÐ >> |